LitCovid-PD-HP

PMC:7317273 / 12448-12455 JSON TXT 2 Projects

‘Primed’ Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients Abstract The COVID19 pandemic, designated as a public health crisis by the World Health Organization (WHO), is rapidly spreading around the world impacting the health and economy of almost all the countries. The data of hospitalized COVID19 patients, especially those with serious illness, indicate the involvement of immunopathological complications. As no effective treatment is currently available, we propose ‘Primed’ Mesenchymal Stem Cells (MSCs) as a therapeutic alternative to tackle devastating epidemic. The individual response to MSCs treatment is heterogeneous. During the treatment of infectious pathology, the effectiveness of the treatment may vary based on the disease scenario. Interestingly, when transplanted in vivo, MSCs are governed by the locally regulated microenvironment, suggesting that the restorative variability could be tailored by choosing a priming regimen to specifically correct a given pathology. Therefore, in our opinion, the priming of MSCs could be a novel approach to improve the responses of COVID19 patients. Main Over the past 5 months, the coronavirus disease 2019 (COVID19) pandemic has relentlessly impacted the global population. The first case of COVID19 infection was identified in the Wuhan City of China on December 1, 2019. Since then, the virus has spread to 213 countries and territories, resulting in over 5.3 million confirmed cases and over 340,000 deaths as on May 23, 2020 (https://www.worldometers.info/coronavirus/). People of all ages are vulnerable to COVID19 infection; however, those over 60 years of age and with pre-existing medical conditions, such as cardiovascular disease, diabetes, or high blood pressure, are more prone to fall seriously ill and succumb to the disease. According to the Centers for Disease Control and Prevention, the symptoms of COVID19 include fever, cough, and shortness of breath, fatigue and sudden loss of sense of smell and taste in some cases (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html), though its typical characteristic is pneumonia that requires hospitalization and even death, if not intervened timely. For any therapeutic intervention, the pathological cascade involved in a disease needs to be elucidated. Therefore, identifying the SARS-CoV-2 virus receptor recognition mechanism that regulates its virulence and pathogenesis holds the key to confront the COVID19 epidemic [1]. Structural analysis of SARS-CoV-2 revealed that the enveloped, positive-sense, single-stranded RNA viruses belong to the genus β-coronavirus and have azoonotic origin [2]. Mounting evidence suggests that SARS-CoV-2 primarily spreads through the respiratory tract, either in the form of droplets, respiratory secretions, or direct contact [3]. In addition, the abundant presence of ACE2 protein receptor in lung alveolar epithelial cells facilitates the binding of SARS-CoV-2 spike-S-glycoprotein, and thus, expedites viral infection. This interaction also activates distinct cytokines crucial for antiviral responses. The data of critically severe COVID19 patients revealed the presence of IL-2, IL-6, IL-7, IL-10, TNF-α, GCSF, MCP-1, MIP-1α, and TNF-α [4] to name a few. To date, no specific approved antiviral therapy for the treatment of COVID19 infection is available, except standard supportive care e.g., oxygenation, ventilation, and fluid management, etc., and some non-specific treatments e.g., hydroxychloroquine and chloroquine etc., to ameliorate the symptoms, and some antivirals and protease inhibitors. Thus, to reverse or combat the detrimental effect produced by SARS-CoV-2 virus, there is an urgent need for a reliable therapy. In this context, multipotent mesenchymal stem cells (MSCs) have shown a strong safety and efficacy profile as they have been intensively investigated in preclinical and clinical studies of various lung diseases, including respiratory virus-induced acute respiratory distress syndrome (ARDS) [5, 6]. Over the past years, the MSCs infusion exhibited an excellent safety record as evident in the 871 clinical trials registered in the National Institute of Health database (https://clinicaltrials.gov/ct2/results?cond=Mesenchymal+Stem+Cells&term=&cntry=&state=&city=&dist=), including 117 trials (https://clinicaltrials.gov/ct2/results?cond=mesenchymal+stem+cell&term=pulmonary&cntry=&state=&city=&dist=&Search=Search) on pulmonary complications, to date. On the other hand, 2845 COVID19 trials worldwide as of 23 May 2020 at World Health Organization-International Clinical Trial Registry Platform (https://www.who.int/ictrp/en/) and 29 clinical trials on MSCs and COVID19 as of 23 May 2020 (https://clinicaltrials.gov/ct2/results?cond=mesenchymal+stem+cell&term=COVID19&cntry=&state=&city=&dist=&Search=Search) have been registered at the NIH database. Worth mentioning, that out of 29 clinical trials, one has been withdrawn (trial no. NCT04293692), therefore, as yet, 28 trials have been registered with a participation of approximately 1525 patients. All of the mentioned studies that employ MSCs and COVID19 patients are in early-phase, and either recruiting or yet to recruit the participants. To brief, out of the twenty-four clinical trials UC-MSCs will be utilized in eleven clinical trials, and AD-MSCs will be utilized in six trials, two will employ DPSCs, one with OM-MSCs, three on BM-MSC, and one (NCT04276987) will utilize exosomes derived from allogenic adipose mesenchymal stem cells, also the trail no. NCT043660663, with 60 participants, will be utilizing the MSC-derived exosomes in twenty participants (20/60), twenty will receive MSC only (20/60), and the rest twenty will be treated as control (20/60). Four registries do not reveal the tissue source (Table 1). The minimum age eligibility criteria in all the trials are 18 years, except the trial no. NCT04349631, NCT04362189, and NCT03042143 where child, adult, or aged, all are eligible to get enrolled as participants. None of the above studies have gender restriction, and the minimum follow-up time is 3 months for each of these investigations. The above registries indicate that a majority of studies will employ umbilical cord-derived MSC which seems reasonable for the following reasons: ease of harvest, fast doubling time, high scalability, and since umbilical cord has a high concentration of stem cells, they can provide a large amount of cells. Noteworthy they have faster doubling times, more plasticity, and with no tumorigenicity [7, 8]. They are derived from a discarded tissue, and so have less ethical concern. In our opinion and experience, amongst the cell types used, equally desirable cell type for COVID19 patients is DPSCs, since they too appear to have similar advantages like UC-MSCs. Some of the unique advantages associated with DPSCs are noninvasive isolation, ease of harvest, and easy accessibility, as they reside in the impacted third molar; beside strong therapeutic ability are the key advantages of DPSCs [9]. They show clonogenicity, and higher ex-vivo proliferative capacity [10] compared with MSCs; they are less prone to malignancy [11], and therefore can give rise to sufficient numbers of cells for cell therapy. Compared with umbilical cord stem cells, DPSCs demonstrated delayed cellular senescence [12] which can be correlated to the increased expression of genes related to growth factors [13]. They have minimal ethical concerns, which is otherwise a hurdle often associated with other cell types. In the presence of specific stimuli, they can give rise to several cell types [14, 15]. As per our knowledge, to date, there is only a single pre-clinical investigation [6], apart from a case report [16] that supports the rationale for the use of MSCs in COVID19. Interestingly, the Abu Dhabi Stem Cell Center (ADSCC), UAE has recently supervised a clinical trial on 73 COVID19 patients employing ‘Activated’ MSCs. The study claims that all the participants were successfully treatment and cured relieved of symptoms of the virus by inhaling the treatment into their lungs after it has been nebulized into a fine mist (https://www.khaleejtimes.com/coronaviruspandemic/coronavirus-uaes-stem-cell-treatment-fights-symptoms-of-covid-19-not-cure-it--). The source of the MSCs was patients own blood. However, no further information has been provided, therefore, more detailed information regarding the procedure of stem cell processing and priming, dose and timing of MSCs inhalation, patients’ age and gender, and the follow-up is needed to determine the efficacy of MSCs activation on those patients. Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020 S.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country 1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020 DOC: June 2020 Both 18 Yrs. and older Brazil 2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020 DOC:September 2020 Both 18 Yrs. and older Jordan 3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020 DOC: July 2020 Both 18 to75 Yrs. China 4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020 DOC: July 2021 Both 18 to75 Yrs. – 5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020 DOC: December 2021 Both 18 to70 Yrs. China 6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020 DOC: February 2022 Both 18 to 65 Yrs. China 7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs (MSCs-Exo) DOS: February 2020 DOC: July 2020 Both 18 to75 Yrs. – 8- NCT043 36,254 Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020 DOC: March 2021 Both 18 to 65 Yrs. China 9- NCT043 39,660 Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020 DOC: June 2020 Both 18 to 75 Yrs. China 10- NCT043 46,368 Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID19) I and II Not Recruiting 20 BM-MSCs DOS: April 2020 DOC: December 2020 Both 18 to 75 Yrs. China 11- NCT043 52,803 Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020 DOC: April 2026 Both 18 to 90 Yrs. – 12- NCT043 49,631 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 56 AD-MSCs DOS: May 2020 DOC: December 2020 Both Child, Adult, Older Adult United States 13- NCT030 42,143 Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID19) (REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019 DOC: October 2022 Both 16 Yrs. and older United Kingdom 14- NCT043 90,152 Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020 DOC: May 2021 Both 18 to 80 Yrs. Colombia 15- NCT043 82,547 Treatment of COVID19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosaderived Mesenchymal Stem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020 DOC: June 2021 Both 18 to70 Yrs. Belarus 16- NCT043 66,323 Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020 DOC: October 2021 Both 18 to 80 Yrs. – 17- NCT043 66,063 Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020 DOC: December 2020 Both 18 to 65 Yrs. Iran 18- NCT043 77,334 Mesenchymal Stem Cells (MSCs) in Inflammation- Resolution Programs of Coronavirus Disease 2019 (COVID19) Induced Acute Respiratory Distress Syndrome (ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020 DOC: February 2021 Both 18 Yrs. and older Germany 19- NCT043 71,393 MSCs in COVID19 ARDS III Recruiting 300 MSCs Remestemcel-L DOS: April 30, 2020 DOC: April 2022 Both 18 Yrs. and older United States 20- NCT043 62,189 Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020 DOC: October 2020 Both Child, Adult, Older Adult United States 21- NCT043 66,271 Clinical Trial of Allogeneic Mesenchymal Cells from Umbilical Cord Tissue in Patients with COVID19 II Recruiting 106 UC-MSCs DOS: May 2020 DOC: May 2021 Both 40 to 80 Yrs. Spain 22- NCT043 48,435 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020 DOC: April 2021 Both Child, Adult, Older Adult United States 23- NCT043 71,601 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020 DOC: December 2022 Both 18 to 70 Yrs. China 24- NCT043 55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020 DOC: May 2021 Both 18 Yrs. and older United States 25- NCT043 92,778 Clinical Use of Stem Cells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020 DOC: September 2020 Both 40 to 60 Yrs. Turkey 26- NCT043 97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020 DOC: June 2021 Both 18 to 80 Yrs. – 27- NCT043 90,139 Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients with Respiratory Distress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020 DOC: December 2020 Both 18 to 75 Yrs. Spain 28- NCT042 69,525 Umbilical Cord (UC)- Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020 DOC: September 2020 Both 18 to 75 Yrs. China Interestingly, the data obtained from a single-center, open-labeled pilot investigation in COVID19 patients from China demonstrated that the treatment with MSCs improved disease-associated parameters in severe and critically severe patients [16]. To brief, seven patients (one critically severe, four severe, and two having common symptoms of pneumonia) were enrolled in the treatment group, where as three patients served as placebo controls (all displaying severe symptoms). All treated patients received a single dose of 1X106 MSCs/kg body weight. Remarkably, all seven showed improvement over two weeks with no noticeable adverse effect, thereby, demonstrated the safe and effective infusion of ACE2–ve MSCs in COVID19 pneumonia patients. The overall improvement in the MSCs infused group was striking as within 2 days after treatment pulmonary functions and symptoms of all the seven patients significantly improved, and most tested negative for the SARS-CoV-2 nucleic acid test over two weeks after MSCs infusion. After 6 days of infusion, the therapy inhibited the over-activation of the immune system by inhibiting CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells. It also decreased TNF-α and enhanced the number of peripheral lymphocytes, CD14+CD11c+CD11bmid regulatory DC, and anti-inflammatory cytokine IL-10. Moreover, the gene expression profile revealed that MSC was ACE2-ve and TMPRSS2-ve, which indicates that the MSCs would not be susceptible to SARS-CoV2 infection. Finally, the RNA sequencing and gene expression analysis showed that MSCs were closely involved in the anti-viral pathways, and had anti-inflammatory trophic activities [6]. In line with above findings, the results from a case report on COVID19 [16] and a study on influenza virus H9NA [5], which shares complications similar to COVID19 like ARDS and lung failure, demonstrated that MSCs can offer therapy for virally-induced pulmonary complications in clinical settings. While all these studies have provided new insights into the protective mechanism of MSCs during viral infection, a few short comings were noticed in these treatments. For example, similar to study conducted by ADSCC, there is also a lack of information on MSCs processing and screening before infusion, and the long-term follow-up of patients etc. For a protocol to be implicated in a larger cohort, optimal information regarding MSCs as well as patients needs to be investigated in a rationally designed controlled setting. Concerning the underlying mechanism by which MSCs exert a beneficial effect, the ability to home [17], engraft [17] and transdifferentiate into the target tissue, which is the infected lung in the present case, besides the bystander effect and immunomodulatory potential [9, 18, 19], are well documented. Also, the anti-apoptotic, anti-viral, and anti-bacterial functions of this therapy have been well known [20]. Under homeostatic conditions, MSCs are hypo-immunogenic and have immune evasion capabilities [21], indicating their suitability for allogeneic transplantation. Despite years of success in MSC research, some of the challenges faced for successful transplantation therapy include heterogeneous treatment response, low number, and source-specific immunomodulatory response [22]. Interestingly, the reparative effects noticed in vivo indicate that clinical efficacy depends on the microenvironment of the transplants [23]. Therefore, the therapeutic capability of MSCs can be regulated and is an attractive area for investigation. However, resting stage MSCs do not show the above potentials; it is only when they are exposed to a stimuli milieu, they demonstrate immunomodulatory or homing potentials [24, 25]. This indicates that the modulatory activity is not constitutively expressed by MSCs but is determined by the process of ‘priming’ to be obtained. Therefore, the empowerment of MSCs by priming before a clinical application may be a potential solution to overcome the challenges that hinder the effectiveness of MSC outcomes. Priming, with inflammatory cytokines, is a process to modulate biological, biochemical or biophysical features that can influence cell fate [26, 27]. In recent years, several approaches have been proposed to improve the effectiveness, endurance and therapeutic efficiency of MSCs [28, 29]. Worth mentioning, the approaches utilizing MSCs, and especially the primed MSCs, could be vital for the success of cell therapy in lung complications, as the intravenously infused MSCs often get trapped in the lung; however, the retention time of MSCs within the lung is extremely short [30]. Though, the alteration in holding capacity of lung in a diseased scenario cannot be ruled out. As primed MSCs could efficiently enhance retention [31], beside intensifying homing [17], and survival [32] in damaged lung, therefore, activation via priming could be a crucial mechanism for retention and engraftment of MSCs in a diseased lung, subsequently providing benefits to the lung through multiple mechanisms. Priming perspectives and MSCs robustness are currently under development. Pre-treating MSCs before injection may enhance the expression of fitness markers and stimulate greater therapeutic outcome. For instance, reports suggest cytokine mediated activation of MSCs lead to strong immunosuppressive behavior, and thereby attenuation of lung injury in rodents [31, 33], however some contradictory findings are also available as no effective role of proinflammatory cytokine priming was observed on MSCs in a model of acute lung injury and ARDS [34]. Therefore, the effect of cytokine priming needs to be further verified to prove the efficacy of primed MSCs in lung anomalies. Besides cytokines, priming of MSCs by growth factors is also a potent mechanism for MSC activation before infusion in pulmonary diseases [35]. Likewise, hypoxia preconditioning can also improve the proliferation and therapeutic efficacy of MSCs, as evident in bleomycin-induced pulmonary fibrosis model [36]. Further, employing pharmacological agents such as paclitaxel to prime MSCs could also be helpful in improving lung anomalies [37]. Therefore, in line with above findings it could reasonably by presume that MSC priming is a significant approach for treating pulmonary anomalies. In the light of above findings, herein, we propose that the mechanism of priming of MSC could be implied to the following: i) Licensing by pro-inflammatory cytokines such as IFN-γ, TNF-α, etc., to enhance immunosuppressive potential; ii) Priming by non-cytokines stimuli such as hormones/growth factors like HGF to boost defensive and protective cellular mechanisms; iii) Pre-conditioning by hypoxia, and/or pharmacological agents, e.g., sphingosine-1-phosphate, etc., to enhance engraftment and reparative effects; iv) Activation by spheroid culturing to enhance homing, survival, differentiation, and lineage specificity e.g. angiogenic mechanism; v) The timing of MSCs engraftment and engagement in the process of activation of immune cells to achieve the most excellent beneficial effect of MSCs infusion. Nevertheless, there are several limitations associated with the priming approaches that may jeopardize MSC based therapies at clinics; hence these challenges must be overcome to harness the true potential of MSCs. For instance, the priming of MSCs by proinflammatory cytokines may negatively affect the MHC class I and class II level; Hormones and/or growth factors may affect the differentiation capacity of MSCs; Priming by hypoxia may induce oxidative stress in MSCs; Growth factors may negatively affect the differentiation capacity of MSCs; Spheroid cultures owing to the variability in their size may lead to the necrotic spheroid core, thus, may interfere with the effectiveness of MSCs after transplantation. Further, the variations in results due to the heterogeneous nature of MSCs [23], and high cost associated with priming protocols, etc., are the considerable hindrances in the successful translation of primed MSCs to the clinic. For instance, not all the priming stimulus, even the same stimuli, shows a similar effect on the cells. Therefore, the effect of individual licensing stimuli should be accessed before being employed at a manufacturing scale. For example, IFN-γ can inhibit T cell proliferation in the regulation of MSC-mediated immunosuppression [38] and can also increase the capacity of MSCs to produce different subtypes of Tregs [39]. IFN-γ can also promote increased expressions of VCAM-1 and ICAM-1 on the surface of MSCs [40]. Similarly, the adjustment of MSC infusion timing may reveal the accurate description of inflammatory surroundings related to a specific disease [41]. This may also explain why MSCs do not always exhibit beneficial effects, even in the same disease. Therefore, it is of great importance to choose the right stimuli in the right dose at and for the right timing, besides fitness of MSCs, fresh vs. cryopreserved, MSCs passage number, and route of delivery to assure homogenous clinical outcomes (Fig. 1). Fig. 1 Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities) To conclude, since its emergence, COVID19 has turned out to be the top priority of the healthcare system. Although stem cell treatment has not yet been proven to eliminate coronavirus completely, preliminary results are promising, suggesting that the diseased patients, under the treatment, might be more amenable to survive the infection. The effect of priming on MSCs’ therapeutic potential has been extensively researched and continues to be investigated. The results of such efforts are eagerly anticipated, as these will pave a way for a strong foundation for future scientific research and clinical applications for a variety of diseases including pulmonary complications. Finally, bearing in mind the desires for mitigation of the existing pandemic, the effectiveness of MSCs in virally infected acute respiratory diseases symptoms, and the pieces of evidence from priming strategies for MSCs, we hypothesize that endorsing priming may enhance the effectiveness of MSCs for long-term benefits which is a prerequisite for the success of stem cell therapy in COVID19 patients. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. We extend our thanks to Mr. Hari Shankar, Era University, for the precious suggestions and support in writing this manuscript. Author Contributions SSR designed, drafted and edited the manuscript. PS and MAK reviewed the manuscript. All the authors have approved the final article. Funding Information This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Compliance with Ethical Standards Disclosure of Competing Interest The authors declare no conflicts of interest. Abbreviations IL-2 interleukin 2 IL-6 interleukin 6 IL-7 interleukin 7 IL-10 interleukin 10 IFN-γ Interferon gamma TNF-α Tumor Necrosis Factor alpha MCP-1 Monocyte Chemoattractant Protein 1 MIP-1α Macrophage Inflammatory Proteins 1 alpha GCSF Granulocyte Colony Stimulating Factor VCAM-1 Vascular Cell Adhesion Molecule-1 ICAM-1 Intracelullar Adhesion Molecule-1 HGF Hepatocyte growth factor BM-MSC Bone Marrow derived Mesenchymal Stem Cell AD-MSC Adipose derived Mesenchyma l Stem Cell UC-MSC Umbilical Cord derived Mesenchymal Stem Cell WJ-MSC Warton Jelly derived Mesenchymal Stem Cell OM-MSC Olfactory Mucosa derived Mesenchymal Stem Cell DPSC Dental Pulp Stem Cell NK Cells Natural Killer Cells DC Dendritic Cells

Document structure show

article-title	‘Primed’ Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients
abstract	The COVID19 pandemic, designated as a public health crisis by the World Health Organization (WHO), is rapidly spreading around the world impacting the health and economy of almost all the countries. The data of hospitalized COVID19 patients, especially those with serious illness, indicate the involvement of immunopathological complications. As no effective treatment is currently available, we propose ‘Primed’ Mesenchymal Stem Cells (MSCs) as a therapeutic alternative to tackle devastating epidemic. The individual response to MSCs treatment is heterogeneous. During the treatment of infectious pathology, the effectiveness of the treatment may vary based on the disease scenario. Interestingly, when transplanted in vivo, MSCs are governed by the locally regulated microenvironment, suggesting that the restorative variability could be tailored by choosing a priming regimen to specifically correct a given pathology. Therefore, in our opinion, the priming of MSCs could be a novel approach to improve the responses of COVID19 patients.
p	The COVID19 pandemic, designated as a public health crisis by the World Health Organization (WHO), is rapidly spreading around the world impacting the health and economy of almost all the countries. The data of hospitalized COVID19 patients, especially those with serious illness, indicate the involvement of immunopathological complications. As no effective treatment is currently available, we propose ‘Primed’ Mesenchymal Stem Cells (MSCs) as a therapeutic alternative to tackle devastating epidemic. The individual response to MSCs treatment is heterogeneous. During the treatment of infectious pathology, the effectiveness of the treatment may vary based on the disease scenario. Interestingly, when transplanted in vivo, MSCs are governed by the locally regulated microenvironment, suggesting that the restorative variability could be tailored by choosing a priming regimen to specifically correct a given pathology. Therefore, in our opinion, the priming of MSCs could be a novel approach to improve the responses of COVID19 patients.
body	Main Over the past 5 months, the coronavirus disease 2019 (COVID19) pandemic has relentlessly impacted the global population. The first case of COVID19 infection was identified in the Wuhan City of China on December 1, 2019. Since then, the virus has spread to 213 countries and territories, resulting in over 5.3 million confirmed cases and over 340,000 deaths as on May 23, 2020 (https://www.worldometers.info/coronavirus/). People of all ages are vulnerable to COVID19 infection; however, those over 60 years of age and with pre-existing medical conditions, such as cardiovascular disease, diabetes, or high blood pressure, are more prone to fall seriously ill and succumb to the disease. According to the Centers for Disease Control and Prevention, the symptoms of COVID19 include fever, cough, and shortness of breath, fatigue and sudden loss of sense of smell and taste in some cases (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html), though its typical characteristic is pneumonia that requires hospitalization and even death, if not intervened timely. For any therapeutic intervention, the pathological cascade involved in a disease needs to be elucidated. Therefore, identifying the SARS-CoV-2 virus receptor recognition mechanism that regulates its virulence and pathogenesis holds the key to confront the COVID19 epidemic [1]. Structural analysis of SARS-CoV-2 revealed that the enveloped, positive-sense, single-stranded RNA viruses belong to the genus β-coronavirus and have azoonotic origin [2]. Mounting evidence suggests that SARS-CoV-2 primarily spreads through the respiratory tract, either in the form of droplets, respiratory secretions, or direct contact [3]. In addition, the abundant presence of ACE2 protein receptor in lung alveolar epithelial cells facilitates the binding of SARS-CoV-2 spike-S-glycoprotein, and thus, expedites viral infection. This interaction also activates distinct cytokines crucial for antiviral responses. The data of critically severe COVID19 patients revealed the presence of IL-2, IL-6, IL-7, IL-10, TNF-α, GCSF, MCP-1, MIP-1α, and TNF-α [4] to name a few. To date, no specific approved antiviral therapy for the treatment of COVID19 infection is available, except standard supportive care e.g., oxygenation, ventilation, and fluid management, etc., and some non-specific treatments e.g., hydroxychloroquine and chloroquine etc., to ameliorate the symptoms, and some antivirals and protease inhibitors. Thus, to reverse or combat the detrimental effect produced by SARS-CoV-2 virus, there is an urgent need for a reliable therapy. In this context, multipotent mesenchymal stem cells (MSCs) have shown a strong safety and efficacy profile as they have been intensively investigated in preclinical and clinical studies of various lung diseases, including respiratory virus-induced acute respiratory distress syndrome (ARDS) [5, 6]. Over the past years, the MSCs infusion exhibited an excellent safety record as evident in the 871 clinical trials registered in the National Institute of Health database (https://clinicaltrials.gov/ct2/results?cond=Mesenchymal+Stem+Cells&term=&cntry=&state=&city=&dist=), including 117 trials (https://clinicaltrials.gov/ct2/results?cond=mesenchymal+stem+cell&term=pulmonary&cntry=&state=&city=&dist=&Search=Search) on pulmonary complications, to date. On the other hand, 2845 COVID19 trials worldwide as of 23 May 2020 at World Health Organization-International Clinical Trial Registry Platform (https://www.who.int/ictrp/en/) and 29 clinical trials on MSCs and COVID19 as of 23 May 2020 (https://clinicaltrials.gov/ct2/results?cond=mesenchymal+stem+cell&term=COVID19&cntry=&state=&city=&dist=&Search=Search) have been registered at the NIH database. Worth mentioning, that out of 29 clinical trials, one has been withdrawn (trial no. NCT04293692), therefore, as yet, 28 trials have been registered with a participation of approximately 1525 patients. All of the mentioned studies that employ MSCs and COVID19 patients are in early-phase, and either recruiting or yet to recruit the participants. To brief, out of the twenty-four clinical trials UC-MSCs will be utilized in eleven clinical trials, and AD-MSCs will be utilized in six trials, two will employ DPSCs, one with OM-MSCs, three on BM-MSC, and one (NCT04276987) will utilize exosomes derived from allogenic adipose mesenchymal stem cells, also the trail no. NCT043660663, with 60 participants, will be utilizing the MSC-derived exosomes in twenty participants (20/60), twenty will receive MSC only (20/60), and the rest twenty will be treated as control (20/60). Four registries do not reveal the tissue source (Table 1). The minimum age eligibility criteria in all the trials are 18 years, except the trial no. NCT04349631, NCT04362189, and NCT03042143 where child, adult, or aged, all are eligible to get enrolled as participants. None of the above studies have gender restriction, and the minimum follow-up time is 3 months for each of these investigations. The above registries indicate that a majority of studies will employ umbilical cord-derived MSC which seems reasonable for the following reasons: ease of harvest, fast doubling time, high scalability, and since umbilical cord has a high concentration of stem cells, they can provide a large amount of cells. Noteworthy they have faster doubling times, more plasticity, and with no tumorigenicity [7, 8]. They are derived from a discarded tissue, and so have less ethical concern. In our opinion and experience, amongst the cell types used, equally desirable cell type for COVID19 patients is DPSCs, since they too appear to have similar advantages like UC-MSCs. Some of the unique advantages associated with DPSCs are noninvasive isolation, ease of harvest, and easy accessibility, as they reside in the impacted third molar; beside strong therapeutic ability are the key advantages of DPSCs [9]. They show clonogenicity, and higher ex-vivo proliferative capacity [10] compared with MSCs; they are less prone to malignancy [11], and therefore can give rise to sufficient numbers of cells for cell therapy. Compared with umbilical cord stem cells, DPSCs demonstrated delayed cellular senescence [12] which can be correlated to the increased expression of genes related to growth factors [13]. They have minimal ethical concerns, which is otherwise a hurdle often associated with other cell types. In the presence of specific stimuli, they can give rise to several cell types [14, 15]. As per our knowledge, to date, there is only a single pre-clinical investigation [6], apart from a case report [16] that supports the rationale for the use of MSCs in COVID19. Interestingly, the Abu Dhabi Stem Cell Center (ADSCC), UAE has recently supervised a clinical trial on 73 COVID19 patients employing ‘Activated’ MSCs. The study claims that all the participants were successfully treatment and cured relieved of symptoms of the virus by inhaling the treatment into their lungs after it has been nebulized into a fine mist (https://www.khaleejtimes.com/coronaviruspandemic/coronavirus-uaes-stem-cell-treatment-fights-symptoms-of-covid-19-not-cure-it--). The source of the MSCs was patients own blood. However, no further information has been provided, therefore, more detailed information regarding the procedure of stem cell processing and priming, dose and timing of MSCs inhalation, patients’ age and gender, and the follow-up is needed to determine the efficacy of MSCs activation on those patients. Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020 S.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country 1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020 DOC: June 2020 Both 18 Yrs. and older Brazil 2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020 DOC:September 2020 Both 18 Yrs. and older Jordan 3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020 DOC: July 2020 Both 18 to75 Yrs. China 4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020 DOC: July 2021 Both 18 to75 Yrs. – 5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020 DOC: December 2021 Both 18 to70 Yrs. China 6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020 DOC: February 2022 Both 18 to 65 Yrs. China 7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs (MSCs-Exo) DOS: February 2020 DOC: July 2020 Both 18 to75 Yrs. – 8- NCT043 36,254 Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020 DOC: March 2021 Both 18 to 65 Yrs. China 9- NCT043 39,660 Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020 DOC: June 2020 Both 18 to 75 Yrs. China 10- NCT043 46,368 Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID19) I and II Not Recruiting 20 BM-MSCs DOS: April 2020 DOC: December 2020 Both 18 to 75 Yrs. China 11- NCT043 52,803 Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020 DOC: April 2026 Both 18 to 90 Yrs. – 12- NCT043 49,631 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 56 AD-MSCs DOS: May 2020 DOC: December 2020 Both Child, Adult, Older Adult United States 13- NCT030 42,143 Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID19) (REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019 DOC: October 2022 Both 16 Yrs. and older United Kingdom 14- NCT043 90,152 Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020 DOC: May 2021 Both 18 to 80 Yrs. Colombia 15- NCT043 82,547 Treatment of COVID19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosaderived Mesenchymal Stem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020 DOC: June 2021 Both 18 to70 Yrs. Belarus 16- NCT043 66,323 Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020 DOC: October 2021 Both 18 to 80 Yrs. – 17- NCT043 66,063 Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020 DOC: December 2020 Both 18 to 65 Yrs. Iran 18- NCT043 77,334 Mesenchymal Stem Cells (MSCs) in Inflammation- Resolution Programs of Coronavirus Disease 2019 (COVID19) Induced Acute Respiratory Distress Syndrome (ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020 DOC: February 2021 Both 18 Yrs. and older Germany 19- NCT043 71,393 MSCs in COVID19 ARDS III Recruiting 300 MSCs Remestemcel-L DOS: April 30, 2020 DOC: April 2022 Both 18 Yrs. and older United States 20- NCT043 62,189 Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020 DOC: October 2020 Both Child, Adult, Older Adult United States 21- NCT043 66,271 Clinical Trial of Allogeneic Mesenchymal Cells from Umbilical Cord Tissue in Patients with COVID19 II Recruiting 106 UC-MSCs DOS: May 2020 DOC: May 2021 Both 40 to 80 Yrs. Spain 22- NCT043 48,435 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020 DOC: April 2021 Both Child, Adult, Older Adult United States 23- NCT043 71,601 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020 DOC: December 2022 Both 18 to 70 Yrs. China 24- NCT043 55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020 DOC: May 2021 Both 18 Yrs. and older United States 25- NCT043 92,778 Clinical Use of Stem Cells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020 DOC: September 2020 Both 40 to 60 Yrs. Turkey 26- NCT043 97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020 DOC: June 2021 Both 18 to 80 Yrs. – 27- NCT043 90,139 Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients with Respiratory Distress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020 DOC: December 2020 Both 18 to 75 Yrs. Spain 28- NCT042 69,525 Umbilical Cord (UC)- Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020 DOC: September 2020 Both 18 to 75 Yrs. China Interestingly, the data obtained from a single-center, open-labeled pilot investigation in COVID19 patients from China demonstrated that the treatment with MSCs improved disease-associated parameters in severe and critically severe patients [16]. To brief, seven patients (one critically severe, four severe, and two having common symptoms of pneumonia) were enrolled in the treatment group, where as three patients served as placebo controls (all displaying severe symptoms). All treated patients received a single dose of 1X106 MSCs/kg body weight. Remarkably, all seven showed improvement over two weeks with no noticeable adverse effect, thereby, demonstrated the safe and effective infusion of ACE2–ve MSCs in COVID19 pneumonia patients. The overall improvement in the MSCs infused group was striking as within 2 days after treatment pulmonary functions and symptoms of all the seven patients significantly improved, and most tested negative for the SARS-CoV-2 nucleic acid test over two weeks after MSCs infusion. After 6 days of infusion, the therapy inhibited the over-activation of the immune system by inhibiting CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells. It also decreased TNF-α and enhanced the number of peripheral lymphocytes, CD14+CD11c+CD11bmid regulatory DC, and anti-inflammatory cytokine IL-10. Moreover, the gene expression profile revealed that MSC was ACE2-ve and TMPRSS2-ve, which indicates that the MSCs would not be susceptible to SARS-CoV2 infection. Finally, the RNA sequencing and gene expression analysis showed that MSCs were closely involved in the anti-viral pathways, and had anti-inflammatory trophic activities [6]. In line with above findings, the results from a case report on COVID19 [16] and a study on influenza virus H9NA [5], which shares complications similar to COVID19 like ARDS and lung failure, demonstrated that MSCs can offer therapy for virally-induced pulmonary complications in clinical settings. While all these studies have provided new insights into the protective mechanism of MSCs during viral infection, a few short comings were noticed in these treatments. For example, similar to study conducted by ADSCC, there is also a lack of information on MSCs processing and screening before infusion, and the long-term follow-up of patients etc. For a protocol to be implicated in a larger cohort, optimal information regarding MSCs as well as patients needs to be investigated in a rationally designed controlled setting. Concerning the underlying mechanism by which MSCs exert a beneficial effect, the ability to home [17], engraft [17] and transdifferentiate into the target tissue, which is the infected lung in the present case, besides the bystander effect and immunomodulatory potential [9, 18, 19], are well documented. Also, the anti-apoptotic, anti-viral, and anti-bacterial functions of this therapy have been well known [20]. Under homeostatic conditions, MSCs are hypo-immunogenic and have immune evasion capabilities [21], indicating their suitability for allogeneic transplantation. Despite years of success in MSC research, some of the challenges faced for successful transplantation therapy include heterogeneous treatment response, low number, and source-specific immunomodulatory response [22]. Interestingly, the reparative effects noticed in vivo indicate that clinical efficacy depends on the microenvironment of the transplants [23]. Therefore, the therapeutic capability of MSCs can be regulated and is an attractive area for investigation. However, resting stage MSCs do not show the above potentials; it is only when they are exposed to a stimuli milieu, they demonstrate immunomodulatory or homing potentials [24, 25]. This indicates that the modulatory activity is not constitutively expressed by MSCs but is determined by the process of ‘priming’ to be obtained. Therefore, the empowerment of MSCs by priming before a clinical application may be a potential solution to overcome the challenges that hinder the effectiveness of MSC outcomes. Priming, with inflammatory cytokines, is a process to modulate biological, biochemical or biophysical features that can influence cell fate [26, 27]. In recent years, several approaches have been proposed to improve the effectiveness, endurance and therapeutic efficiency of MSCs [28, 29]. Worth mentioning, the approaches utilizing MSCs, and especially the primed MSCs, could be vital for the success of cell therapy in lung complications, as the intravenously infused MSCs often get trapped in the lung; however, the retention time of MSCs within the lung is extremely short [30]. Though, the alteration in holding capacity of lung in a diseased scenario cannot be ruled out. As primed MSCs could efficiently enhance retention [31], beside intensifying homing [17], and survival [32] in damaged lung, therefore, activation via priming could be a crucial mechanism for retention and engraftment of MSCs in a diseased lung, subsequently providing benefits to the lung through multiple mechanisms. Priming perspectives and MSCs robustness are currently under development. Pre-treating MSCs before injection may enhance the expression of fitness markers and stimulate greater therapeutic outcome. For instance, reports suggest cytokine mediated activation of MSCs lead to strong immunosuppressive behavior, and thereby attenuation of lung injury in rodents [31, 33], however some contradictory findings are also available as no effective role of proinflammatory cytokine priming was observed on MSCs in a model of acute lung injury and ARDS [34]. Therefore, the effect of cytokine priming needs to be further verified to prove the efficacy of primed MSCs in lung anomalies. Besides cytokines, priming of MSCs by growth factors is also a potent mechanism for MSC activation before infusion in pulmonary diseases [35]. Likewise, hypoxia preconditioning can also improve the proliferation and therapeutic efficacy of MSCs, as evident in bleomycin-induced pulmonary fibrosis model [36]. Further, employing pharmacological agents such as paclitaxel to prime MSCs could also be helpful in improving lung anomalies [37]. Therefore, in line with above findings it could reasonably by presume that MSC priming is a significant approach for treating pulmonary anomalies. In the light of above findings, herein, we propose that the mechanism of priming of MSC could be implied to the following: i) Licensing by pro-inflammatory cytokines such as IFN-γ, TNF-α, etc., to enhance immunosuppressive potential; ii) Priming by non-cytokines stimuli such as hormones/growth factors like HGF to boost defensive and protective cellular mechanisms; iii) Pre-conditioning by hypoxia, and/or pharmacological agents, e.g., sphingosine-1-phosphate, etc., to enhance engraftment and reparative effects; iv) Activation by spheroid culturing to enhance homing, survival, differentiation, and lineage specificity e.g. angiogenic mechanism; v) The timing of MSCs engraftment and engagement in the process of activation of immune cells to achieve the most excellent beneficial effect of MSCs infusion. Nevertheless, there are several limitations associated with the priming approaches that may jeopardize MSC based therapies at clinics; hence these challenges must be overcome to harness the true potential of MSCs. For instance, the priming of MSCs by proinflammatory cytokines may negatively affect the MHC class I and class II level; Hormones and/or growth factors may affect the differentiation capacity of MSCs; Priming by hypoxia may induce oxidative stress in MSCs; Growth factors may negatively affect the differentiation capacity of MSCs; Spheroid cultures owing to the variability in their size may lead to the necrotic spheroid core, thus, may interfere with the effectiveness of MSCs after transplantation. Further, the variations in results due to the heterogeneous nature of MSCs [23], and high cost associated with priming protocols, etc., are the considerable hindrances in the successful translation of primed MSCs to the clinic. For instance, not all the priming stimulus, even the same stimuli, shows a similar effect on the cells. Therefore, the effect of individual licensing stimuli should be accessed before being employed at a manufacturing scale. For example, IFN-γ can inhibit T cell proliferation in the regulation of MSC-mediated immunosuppression [38] and can also increase the capacity of MSCs to produce different subtypes of Tregs [39]. IFN-γ can also promote increased expressions of VCAM-1 and ICAM-1 on the surface of MSCs [40]. Similarly, the adjustment of MSC infusion timing may reveal the accurate description of inflammatory surroundings related to a specific disease [41]. This may also explain why MSCs do not always exhibit beneficial effects, even in the same disease. Therefore, it is of great importance to choose the right stimuli in the right dose at and for the right timing, besides fitness of MSCs, fresh vs. cryopreserved, MSCs passage number, and route of delivery to assure homogenous clinical outcomes (Fig. 1). Fig. 1 Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities) To conclude, since its emergence, COVID19 has turned out to be the top priority of the healthcare system. Although stem cell treatment has not yet been proven to eliminate coronavirus completely, preliminary results are promising, suggesting that the diseased patients, under the treatment, might be more amenable to survive the infection. The effect of priming on MSCs’ therapeutic potential has been extensively researched and continues to be investigated. The results of such efforts are eagerly anticipated, as these will pave a way for a strong foundation for future scientific research and clinical applications for a variety of diseases including pulmonary complications. Finally, bearing in mind the desires for mitigation of the existing pandemic, the effectiveness of MSCs in virally infected acute respiratory diseases symptoms, and the pieces of evidence from priming strategies for MSCs, we hypothesize that endorsing priming may enhance the effectiveness of MSCs for long-term benefits which is a prerequisite for the success of stem cell therapy in COVID19 patients.
sec	Main Over the past 5 months, the coronavirus disease 2019 (COVID19) pandemic has relentlessly impacted the global population. The first case of COVID19 infection was identified in the Wuhan City of China on December 1, 2019. Since then, the virus has spread to 213 countries and territories, resulting in over 5.3 million confirmed cases and over 340,000 deaths as on May 23, 2020 (https://www.worldometers.info/coronavirus/). People of all ages are vulnerable to COVID19 infection; however, those over 60 years of age and with pre-existing medical conditions, such as cardiovascular disease, diabetes, or high blood pressure, are more prone to fall seriously ill and succumb to the disease. According to the Centers for Disease Control and Prevention, the symptoms of COVID19 include fever, cough, and shortness of breath, fatigue and sudden loss of sense of smell and taste in some cases (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html), though its typical characteristic is pneumonia that requires hospitalization and even death, if not intervened timely. For any therapeutic intervention, the pathological cascade involved in a disease needs to be elucidated. Therefore, identifying the SARS-CoV-2 virus receptor recognition mechanism that regulates its virulence and pathogenesis holds the key to confront the COVID19 epidemic [1]. Structural analysis of SARS-CoV-2 revealed that the enveloped, positive-sense, single-stranded RNA viruses belong to the genus β-coronavirus and have azoonotic origin [2]. Mounting evidence suggests that SARS-CoV-2 primarily spreads through the respiratory tract, either in the form of droplets, respiratory secretions, or direct contact [3]. In addition, the abundant presence of ACE2 protein receptor in lung alveolar epithelial cells facilitates the binding of SARS-CoV-2 spike-S-glycoprotein, and thus, expedites viral infection. This interaction also activates distinct cytokines crucial for antiviral responses. The data of critically severe COVID19 patients revealed the presence of IL-2, IL-6, IL-7, IL-10, TNF-α, GCSF, MCP-1, MIP-1α, and TNF-α [4] to name a few. To date, no specific approved antiviral therapy for the treatment of COVID19 infection is available, except standard supportive care e.g., oxygenation, ventilation, and fluid management, etc., and some non-specific treatments e.g., hydroxychloroquine and chloroquine etc., to ameliorate the symptoms, and some antivirals and protease inhibitors. Thus, to reverse or combat the detrimental effect produced by SARS-CoV-2 virus, there is an urgent need for a reliable therapy. In this context, multipotent mesenchymal stem cells (MSCs) have shown a strong safety and efficacy profile as they have been intensively investigated in preclinical and clinical studies of various lung diseases, including respiratory virus-induced acute respiratory distress syndrome (ARDS) [5, 6]. Over the past years, the MSCs infusion exhibited an excellent safety record as evident in the 871 clinical trials registered in the National Institute of Health database (https://clinicaltrials.gov/ct2/results?cond=Mesenchymal+Stem+Cells&term=&cntry=&state=&city=&dist=), including 117 trials (https://clinicaltrials.gov/ct2/results?cond=mesenchymal+stem+cell&term=pulmonary&cntry=&state=&city=&dist=&Search=Search) on pulmonary complications, to date. On the other hand, 2845 COVID19 trials worldwide as of 23 May 2020 at World Health Organization-International Clinical Trial Registry Platform (https://www.who.int/ictrp/en/) and 29 clinical trials on MSCs and COVID19 as of 23 May 2020 (https://clinicaltrials.gov/ct2/results?cond=mesenchymal+stem+cell&term=COVID19&cntry=&state=&city=&dist=&Search=Search) have been registered at the NIH database. Worth mentioning, that out of 29 clinical trials, one has been withdrawn (trial no. NCT04293692), therefore, as yet, 28 trials have been registered with a participation of approximately 1525 patients. All of the mentioned studies that employ MSCs and COVID19 patients are in early-phase, and either recruiting or yet to recruit the participants. To brief, out of the twenty-four clinical trials UC-MSCs will be utilized in eleven clinical trials, and AD-MSCs will be utilized in six trials, two will employ DPSCs, one with OM-MSCs, three on BM-MSC, and one (NCT04276987) will utilize exosomes derived from allogenic adipose mesenchymal stem cells, also the trail no. NCT043660663, with 60 participants, will be utilizing the MSC-derived exosomes in twenty participants (20/60), twenty will receive MSC only (20/60), and the rest twenty will be treated as control (20/60). Four registries do not reveal the tissue source (Table 1). The minimum age eligibility criteria in all the trials are 18 years, except the trial no. NCT04349631, NCT04362189, and NCT03042143 where child, adult, or aged, all are eligible to get enrolled as participants. None of the above studies have gender restriction, and the minimum follow-up time is 3 months for each of these investigations. The above registries indicate that a majority of studies will employ umbilical cord-derived MSC which seems reasonable for the following reasons: ease of harvest, fast doubling time, high scalability, and since umbilical cord has a high concentration of stem cells, they can provide a large amount of cells. Noteworthy they have faster doubling times, more plasticity, and with no tumorigenicity [7, 8]. They are derived from a discarded tissue, and so have less ethical concern. In our opinion and experience, amongst the cell types used, equally desirable cell type for COVID19 patients is DPSCs, since they too appear to have similar advantages like UC-MSCs. Some of the unique advantages associated with DPSCs are noninvasive isolation, ease of harvest, and easy accessibility, as they reside in the impacted third molar; beside strong therapeutic ability are the key advantages of DPSCs [9]. They show clonogenicity, and higher ex-vivo proliferative capacity [10] compared with MSCs; they are less prone to malignancy [11], and therefore can give rise to sufficient numbers of cells for cell therapy. Compared with umbilical cord stem cells, DPSCs demonstrated delayed cellular senescence [12] which can be correlated to the increased expression of genes related to growth factors [13]. They have minimal ethical concerns, which is otherwise a hurdle often associated with other cell types. In the presence of specific stimuli, they can give rise to several cell types [14, 15]. As per our knowledge, to date, there is only a single pre-clinical investigation [6], apart from a case report [16] that supports the rationale for the use of MSCs in COVID19. Interestingly, the Abu Dhabi Stem Cell Center (ADSCC), UAE has recently supervised a clinical trial on 73 COVID19 patients employing ‘Activated’ MSCs. The study claims that all the participants were successfully treatment and cured relieved of symptoms of the virus by inhaling the treatment into their lungs after it has been nebulized into a fine mist (https://www.khaleejtimes.com/coronaviruspandemic/coronavirus-uaes-stem-cell-treatment-fights-symptoms-of-covid-19-not-cure-it--). The source of the MSCs was patients own blood. However, no further information has been provided, therefore, more detailed information regarding the procedure of stem cell processing and priming, dose and timing of MSCs inhalation, patients’ age and gender, and the follow-up is needed to determine the efficacy of MSCs activation on those patients. Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020 S.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country 1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020 DOC: June 2020 Both 18 Yrs. and older Brazil 2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020 DOC:September 2020 Both 18 Yrs. and older Jordan 3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020 DOC: July 2020 Both 18 to75 Yrs. China 4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020 DOC: July 2021 Both 18 to75 Yrs. – 5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020 DOC: December 2021 Both 18 to70 Yrs. China 6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020 DOC: February 2022 Both 18 to 65 Yrs. China 7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs (MSCs-Exo) DOS: February 2020 DOC: July 2020 Both 18 to75 Yrs. – 8- NCT043 36,254 Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020 DOC: March 2021 Both 18 to 65 Yrs. China 9- NCT043 39,660 Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020 DOC: June 2020 Both 18 to 75 Yrs. China 10- NCT043 46,368 Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID19) I and II Not Recruiting 20 BM-MSCs DOS: April 2020 DOC: December 2020 Both 18 to 75 Yrs. China 11- NCT043 52,803 Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020 DOC: April 2026 Both 18 to 90 Yrs. – 12- NCT043 49,631 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 56 AD-MSCs DOS: May 2020 DOC: December 2020 Both Child, Adult, Older Adult United States 13- NCT030 42,143 Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID19) (REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019 DOC: October 2022 Both 16 Yrs. and older United Kingdom 14- NCT043 90,152 Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020 DOC: May 2021 Both 18 to 80 Yrs. Colombia 15- NCT043 82,547 Treatment of COVID19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosaderived Mesenchymal Stem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020 DOC: June 2021 Both 18 to70 Yrs. Belarus 16- NCT043 66,323 Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020 DOC: October 2021 Both 18 to 80 Yrs. – 17- NCT043 66,063 Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020 DOC: December 2020 Both 18 to 65 Yrs. Iran 18- NCT043 77,334 Mesenchymal Stem Cells (MSCs) in Inflammation- Resolution Programs of Coronavirus Disease 2019 (COVID19) Induced Acute Respiratory Distress Syndrome (ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020 DOC: February 2021 Both 18 Yrs. and older Germany 19- NCT043 71,393 MSCs in COVID19 ARDS III Recruiting 300 MSCs Remestemcel-L DOS: April 30, 2020 DOC: April 2022 Both 18 Yrs. and older United States 20- NCT043 62,189 Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020 DOC: October 2020 Both Child, Adult, Older Adult United States 21- NCT043 66,271 Clinical Trial of Allogeneic Mesenchymal Cells from Umbilical Cord Tissue in Patients with COVID19 II Recruiting 106 UC-MSCs DOS: May 2020 DOC: May 2021 Both 40 to 80 Yrs. Spain 22- NCT043 48,435 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020 DOC: April 2021 Both Child, Adult, Older Adult United States 23- NCT043 71,601 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020 DOC: December 2022 Both 18 to 70 Yrs. China 24- NCT043 55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020 DOC: May 2021 Both 18 Yrs. and older United States 25- NCT043 92,778 Clinical Use of Stem Cells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020 DOC: September 2020 Both 40 to 60 Yrs. Turkey 26- NCT043 97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020 DOC: June 2021 Both 18 to 80 Yrs. – 27- NCT043 90,139 Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients with Respiratory Distress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020 DOC: December 2020 Both 18 to 75 Yrs. Spain 28- NCT042 69,525 Umbilical Cord (UC)- Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020 DOC: September 2020 Both 18 to 75 Yrs. China Interestingly, the data obtained from a single-center, open-labeled pilot investigation in COVID19 patients from China demonstrated that the treatment with MSCs improved disease-associated parameters in severe and critically severe patients [16]. To brief, seven patients (one critically severe, four severe, and two having common symptoms of pneumonia) were enrolled in the treatment group, where as three patients served as placebo controls (all displaying severe symptoms). All treated patients received a single dose of 1X106 MSCs/kg body weight. Remarkably, all seven showed improvement over two weeks with no noticeable adverse effect, thereby, demonstrated the safe and effective infusion of ACE2–ve MSCs in COVID19 pneumonia patients. The overall improvement in the MSCs infused group was striking as within 2 days after treatment pulmonary functions and symptoms of all the seven patients significantly improved, and most tested negative for the SARS-CoV-2 nucleic acid test over two weeks after MSCs infusion. After 6 days of infusion, the therapy inhibited the over-activation of the immune system by inhibiting CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells. It also decreased TNF-α and enhanced the number of peripheral lymphocytes, CD14+CD11c+CD11bmid regulatory DC, and anti-inflammatory cytokine IL-10. Moreover, the gene expression profile revealed that MSC was ACE2-ve and TMPRSS2-ve, which indicates that the MSCs would not be susceptible to SARS-CoV2 infection. Finally, the RNA sequencing and gene expression analysis showed that MSCs were closely involved in the anti-viral pathways, and had anti-inflammatory trophic activities [6]. In line with above findings, the results from a case report on COVID19 [16] and a study on influenza virus H9NA [5], which shares complications similar to COVID19 like ARDS and lung failure, demonstrated that MSCs can offer therapy for virally-induced pulmonary complications in clinical settings. While all these studies have provided new insights into the protective mechanism of MSCs during viral infection, a few short comings were noticed in these treatments. For example, similar to study conducted by ADSCC, there is also a lack of information on MSCs processing and screening before infusion, and the long-term follow-up of patients etc. For a protocol to be implicated in a larger cohort, optimal information regarding MSCs as well as patients needs to be investigated in a rationally designed controlled setting. Concerning the underlying mechanism by which MSCs exert a beneficial effect, the ability to home [17], engraft [17] and transdifferentiate into the target tissue, which is the infected lung in the present case, besides the bystander effect and immunomodulatory potential [9, 18, 19], are well documented. Also, the anti-apoptotic, anti-viral, and anti-bacterial functions of this therapy have been well known [20]. Under homeostatic conditions, MSCs are hypo-immunogenic and have immune evasion capabilities [21], indicating their suitability for allogeneic transplantation. Despite years of success in MSC research, some of the challenges faced for successful transplantation therapy include heterogeneous treatment response, low number, and source-specific immunomodulatory response [22]. Interestingly, the reparative effects noticed in vivo indicate that clinical efficacy depends on the microenvironment of the transplants [23]. Therefore, the therapeutic capability of MSCs can be regulated and is an attractive area for investigation. However, resting stage MSCs do not show the above potentials; it is only when they are exposed to a stimuli milieu, they demonstrate immunomodulatory or homing potentials [24, 25]. This indicates that the modulatory activity is not constitutively expressed by MSCs but is determined by the process of ‘priming’ to be obtained. Therefore, the empowerment of MSCs by priming before a clinical application may be a potential solution to overcome the challenges that hinder the effectiveness of MSC outcomes. Priming, with inflammatory cytokines, is a process to modulate biological, biochemical or biophysical features that can influence cell fate [26, 27]. In recent years, several approaches have been proposed to improve the effectiveness, endurance and therapeutic efficiency of MSCs [28, 29]. Worth mentioning, the approaches utilizing MSCs, and especially the primed MSCs, could be vital for the success of cell therapy in lung complications, as the intravenously infused MSCs often get trapped in the lung; however, the retention time of MSCs within the lung is extremely short [30]. Though, the alteration in holding capacity of lung in a diseased scenario cannot be ruled out. As primed MSCs could efficiently enhance retention [31], beside intensifying homing [17], and survival [32] in damaged lung, therefore, activation via priming could be a crucial mechanism for retention and engraftment of MSCs in a diseased lung, subsequently providing benefits to the lung through multiple mechanisms. Priming perspectives and MSCs robustness are currently under development. Pre-treating MSCs before injection may enhance the expression of fitness markers and stimulate greater therapeutic outcome. For instance, reports suggest cytokine mediated activation of MSCs lead to strong immunosuppressive behavior, and thereby attenuation of lung injury in rodents [31, 33], however some contradictory findings are also available as no effective role of proinflammatory cytokine priming was observed on MSCs in a model of acute lung injury and ARDS [34]. Therefore, the effect of cytokine priming needs to be further verified to prove the efficacy of primed MSCs in lung anomalies. Besides cytokines, priming of MSCs by growth factors is also a potent mechanism for MSC activation before infusion in pulmonary diseases [35]. Likewise, hypoxia preconditioning can also improve the proliferation and therapeutic efficacy of MSCs, as evident in bleomycin-induced pulmonary fibrosis model [36]. Further, employing pharmacological agents such as paclitaxel to prime MSCs could also be helpful in improving lung anomalies [37]. Therefore, in line with above findings it could reasonably by presume that MSC priming is a significant approach for treating pulmonary anomalies. In the light of above findings, herein, we propose that the mechanism of priming of MSC could be implied to the following: i) Licensing by pro-inflammatory cytokines such as IFN-γ, TNF-α, etc., to enhance immunosuppressive potential; ii) Priming by non-cytokines stimuli such as hormones/growth factors like HGF to boost defensive and protective cellular mechanisms; iii) Pre-conditioning by hypoxia, and/or pharmacological agents, e.g., sphingosine-1-phosphate, etc., to enhance engraftment and reparative effects; iv) Activation by spheroid culturing to enhance homing, survival, differentiation, and lineage specificity e.g. angiogenic mechanism; v) The timing of MSCs engraftment and engagement in the process of activation of immune cells to achieve the most excellent beneficial effect of MSCs infusion. Nevertheless, there are several limitations associated with the priming approaches that may jeopardize MSC based therapies at clinics; hence these challenges must be overcome to harness the true potential of MSCs. For instance, the priming of MSCs by proinflammatory cytokines may negatively affect the MHC class I and class II level; Hormones and/or growth factors may affect the differentiation capacity of MSCs; Priming by hypoxia may induce oxidative stress in MSCs; Growth factors may negatively affect the differentiation capacity of MSCs; Spheroid cultures owing to the variability in their size may lead to the necrotic spheroid core, thus, may interfere with the effectiveness of MSCs after transplantation. Further, the variations in results due to the heterogeneous nature of MSCs [23], and high cost associated with priming protocols, etc., are the considerable hindrances in the successful translation of primed MSCs to the clinic. For instance, not all the priming stimulus, even the same stimuli, shows a similar effect on the cells. Therefore, the effect of individual licensing stimuli should be accessed before being employed at a manufacturing scale. For example, IFN-γ can inhibit T cell proliferation in the regulation of MSC-mediated immunosuppression [38] and can also increase the capacity of MSCs to produce different subtypes of Tregs [39]. IFN-γ can also promote increased expressions of VCAM-1 and ICAM-1 on the surface of MSCs [40]. Similarly, the adjustment of MSC infusion timing may reveal the accurate description of inflammatory surroundings related to a specific disease [41]. This may also explain why MSCs do not always exhibit beneficial effects, even in the same disease. Therefore, it is of great importance to choose the right stimuli in the right dose at and for the right timing, besides fitness of MSCs, fresh vs. cryopreserved, MSCs passage number, and route of delivery to assure homogenous clinical outcomes (Fig. 1). Fig. 1 Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities) To conclude, since its emergence, COVID19 has turned out to be the top priority of the healthcare system. Although stem cell treatment has not yet been proven to eliminate coronavirus completely, preliminary results are promising, suggesting that the diseased patients, under the treatment, might be more amenable to survive the infection. The effect of priming on MSCs’ therapeutic potential has been extensively researched and continues to be investigated. The results of such efforts are eagerly anticipated, as these will pave a way for a strong foundation for future scientific research and clinical applications for a variety of diseases including pulmonary complications. Finally, bearing in mind the desires for mitigation of the existing pandemic, the effectiveness of MSCs in virally infected acute respiratory diseases symptoms, and the pieces of evidence from priming strategies for MSCs, we hypothesize that endorsing priming may enhance the effectiveness of MSCs for long-term benefits which is a prerequisite for the success of stem cell therapy in COVID19 patients.
title	Main
p	Over the past 5 months, the coronavirus disease 2019 (COVID19) pandemic has relentlessly impacted the global population. The first case of COVID19 infection was identified in the Wuhan City of China on December 1, 2019. Since then, the virus has spread to 213 countries and territories, resulting in over 5.3 million confirmed cases and over 340,000 deaths as on May 23, 2020 (https://www.worldometers.info/coronavirus/). People of all ages are vulnerable to COVID19 infection; however, those over 60 years of age and with pre-existing medical conditions, such as cardiovascular disease, diabetes, or high blood pressure, are more prone to fall seriously ill and succumb to the disease. According to the Centers for Disease Control and Prevention, the symptoms of COVID19 include fever, cough, and shortness of breath, fatigue and sudden loss of sense of smell and taste in some cases (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html), though its typical characteristic is pneumonia that requires hospitalization and even death, if not intervened timely.
p	For any therapeutic intervention, the pathological cascade involved in a disease needs to be elucidated. Therefore, identifying the SARS-CoV-2 virus receptor recognition mechanism that regulates its virulence and pathogenesis holds the key to confront the COVID19 epidemic [1]. Structural analysis of SARS-CoV-2 revealed that the enveloped, positive-sense, single-stranded RNA viruses belong to the genus β-coronavirus and have azoonotic origin [2]. Mounting evidence suggests that SARS-CoV-2 primarily spreads through the respiratory tract, either in the form of droplets, respiratory secretions, or direct contact [3]. In addition, the abundant presence of ACE2 protein receptor in lung alveolar epithelial cells facilitates the binding of SARS-CoV-2 spike-S-glycoprotein, and thus, expedites viral infection. This interaction also activates distinct cytokines crucial for antiviral responses. The data of critically severe COVID19 patients revealed the presence of IL-2, IL-6, IL-7, IL-10, TNF-α, GCSF, MCP-1, MIP-1α, and TNF-α [4] to name a few. To date, no specific approved antiviral therapy for the treatment of COVID19 infection is available, except standard supportive care e.g., oxygenation, ventilation, and fluid management, etc., and some non-specific treatments e.g., hydroxychloroquine and chloroquine etc., to ameliorate the symptoms, and some antivirals and protease inhibitors. Thus, to reverse or combat the detrimental effect produced by SARS-CoV-2 virus, there is an urgent need for a reliable therapy. In this context, multipotent mesenchymal stem cells (MSCs) have shown a strong safety and efficacy profile as they have been intensively investigated in preclinical and clinical studies of various lung diseases, including respiratory virus-induced acute respiratory distress syndrome (ARDS) [5, 6]. Over the past years, the MSCs infusion exhibited an excellent safety record as evident in the 871 clinical trials registered in the National Institute of Health database (https://clinicaltrials.gov/ct2/results?cond=Mesenchymal+Stem+Cells&term=&cntry=&state=&city=&dist=), including 117 trials (https://clinicaltrials.gov/ct2/results?cond=mesenchymal+stem+cell&term=pulmonary&cntry=&state=&city=&dist=&Search=Search) on pulmonary complications, to date. On the other hand, 2845 COVID19 trials worldwide as of 23 May 2020 at World Health Organization-International Clinical Trial Registry Platform (https://www.who.int/ictrp/en/) and 29 clinical trials on MSCs and COVID19 as of 23 May 2020 (https://clinicaltrials.gov/ct2/results?cond=mesenchymal+stem+cell&term=COVID19&cntry=&state=&city=&dist=&Search=Search) have been registered at the NIH database. Worth mentioning, that out of 29 clinical trials, one has been withdrawn (trial no. NCT04293692), therefore, as yet, 28 trials have been registered with a participation of approximately 1525 patients. All of the mentioned studies that employ MSCs and COVID19 patients are in early-phase, and either recruiting or yet to recruit the participants.
p	To brief, out of the twenty-four clinical trials UC-MSCs will be utilized in eleven clinical trials, and AD-MSCs will be utilized in six trials, two will employ DPSCs, one with OM-MSCs, three on BM-MSC, and one (NCT04276987) will utilize exosomes derived from allogenic adipose mesenchymal stem cells, also the trail no. NCT043660663, with 60 participants, will be utilizing the MSC-derived exosomes in twenty participants (20/60), twenty will receive MSC only (20/60), and the rest twenty will be treated as control (20/60). Four registries do not reveal the tissue source (Table 1). The minimum age eligibility criteria in all the trials are 18 years, except the trial no. NCT04349631, NCT04362189, and NCT03042143 where child, adult, or aged, all are eligible to get enrolled as participants. None of the above studies have gender restriction, and the minimum follow-up time is 3 months for each of these investigations. The above registries indicate that a majority of studies will employ umbilical cord-derived MSC which seems reasonable for the following reasons: ease of harvest, fast doubling time, high scalability, and since umbilical cord has a high concentration of stem cells, they can provide a large amount of cells. Noteworthy they have faster doubling times, more plasticity, and with no tumorigenicity [7, 8]. They are derived from a discarded tissue, and so have less ethical concern. In our opinion and experience, amongst the cell types used, equally desirable cell type for COVID19 patients is DPSCs, since they too appear to have similar advantages like UC-MSCs. Some of the unique advantages associated with DPSCs are noninvasive isolation, ease of harvest, and easy accessibility, as they reside in the impacted third molar; beside strong therapeutic ability are the key advantages of DPSCs [9]. They show clonogenicity, and higher ex-vivo proliferative capacity [10] compared with MSCs; they are less prone to malignancy [11], and therefore can give rise to sufficient numbers of cells for cell therapy. Compared with umbilical cord stem cells, DPSCs demonstrated delayed cellular senescence [12] which can be correlated to the increased expression of genes related to growth factors [13]. They have minimal ethical concerns, which is otherwise a hurdle often associated with other cell types. In the presence of specific stimuli, they can give rise to several cell types [14, 15]. As per our knowledge, to date, there is only a single pre-clinical investigation [6], apart from a case report [16] that supports the rationale for the use of MSCs in COVID19. Interestingly, the Abu Dhabi Stem Cell Center (ADSCC), UAE has recently supervised a clinical trial on 73 COVID19 patients employing ‘Activated’ MSCs. The study claims that all the participants were successfully treatment and cured relieved of symptoms of the virus by inhaling the treatment into their lungs after it has been nebulized into a fine mist (https://www.khaleejtimes.com/coronaviruspandemic/coronavirus-uaes-stem-cell-treatment-fights-symptoms-of-covid-19-not-cure-it--). The source of the MSCs was patients own blood. However, no further information has been provided, therefore, more detailed information regarding the procedure of stem cell processing and priming, dose and timing of MSCs inhalation, patients’ age and gender, and the follow-up is needed to determine the efficacy of MSCs activation on those patients. Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020 S.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country 1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020 DOC: June 2020 Both 18 Yrs. and older Brazil 2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020 DOC:September 2020 Both 18 Yrs. and older Jordan 3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020 DOC: July 2020 Both 18 to75 Yrs. China 4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020 DOC: July 2021 Both 18 to75 Yrs. – 5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020 DOC: December 2021 Both 18 to70 Yrs. China 6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020 DOC: February 2022 Both 18 to 65 Yrs. China 7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs (MSCs-Exo) DOS: February 2020 DOC: July 2020 Both 18 to75 Yrs. – 8- NCT043 36,254 Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020 DOC: March 2021 Both 18 to 65 Yrs. China 9- NCT043 39,660 Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020 DOC: June 2020 Both 18 to 75 Yrs. China 10- NCT043 46,368 Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID19) I and II Not Recruiting 20 BM-MSCs DOS: April 2020 DOC: December 2020 Both 18 to 75 Yrs. China 11- NCT043 52,803 Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020 DOC: April 2026 Both 18 to 90 Yrs. – 12- NCT043 49,631 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 56 AD-MSCs DOS: May 2020 DOC: December 2020 Both Child, Adult, Older Adult United States 13- NCT030 42,143 Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID19) (REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019 DOC: October 2022 Both 16 Yrs. and older United Kingdom 14- NCT043 90,152 Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020 DOC: May 2021 Both 18 to 80 Yrs. Colombia 15- NCT043 82,547 Treatment of COVID19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosaderived Mesenchymal Stem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020 DOC: June 2021 Both 18 to70 Yrs. Belarus 16- NCT043 66,323 Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020 DOC: October 2021 Both 18 to 80 Yrs. – 17- NCT043 66,063 Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020 DOC: December 2020 Both 18 to 65 Yrs. Iran 18- NCT043 77,334 Mesenchymal Stem Cells (MSCs) in Inflammation- Resolution Programs of Coronavirus Disease 2019 (COVID19) Induced Acute Respiratory Distress Syndrome (ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020 DOC: February 2021 Both 18 Yrs. and older Germany 19- NCT043 71,393 MSCs in COVID19 ARDS III Recruiting 300 MSCs Remestemcel-L DOS: April 30, 2020 DOC: April 2022 Both 18 Yrs. and older United States 20- NCT043 62,189 Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020 DOC: October 2020 Both Child, Adult, Older Adult United States 21- NCT043 66,271 Clinical Trial of Allogeneic Mesenchymal Cells from Umbilical Cord Tissue in Patients with COVID19 II Recruiting 106 UC-MSCs DOS: May 2020 DOC: May 2021 Both 40 to 80 Yrs. Spain 22- NCT043 48,435 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020 DOC: April 2021 Both Child, Adult, Older Adult United States 23- NCT043 71,601 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020 DOC: December 2022 Both 18 to 70 Yrs. China 24- NCT043 55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020 DOC: May 2021 Both 18 Yrs. and older United States 25- NCT043 92,778 Clinical Use of Stem Cells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020 DOC: September 2020 Both 40 to 60 Yrs. Turkey 26- NCT043 97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020 DOC: June 2021 Both 18 to 80 Yrs. – 27- NCT043 90,139 Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients with Respiratory Distress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020 DOC: December 2020 Both 18 to 75 Yrs. Spain 28- NCT042 69,525 Umbilical Cord (UC)- Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020 DOC: September 2020 Both 18 to 75 Yrs. China
table-wrap	Table 1 Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020 S.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country 1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020 DOC: June 2020 Both 18 Yrs. and older Brazil 2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020 DOC:September 2020 Both 18 Yrs. and older Jordan 3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020 DOC: July 2020 Both 18 to75 Yrs. China 4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020 DOC: July 2021 Both 18 to75 Yrs. – 5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020 DOC: December 2021 Both 18 to70 Yrs. China 6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020 DOC: February 2022 Both 18 to 65 Yrs. China 7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs (MSCs-Exo) DOS: February 2020 DOC: July 2020 Both 18 to75 Yrs. – 8- NCT043 36,254 Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020 DOC: March 2021 Both 18 to 65 Yrs. China 9- NCT043 39,660 Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020 DOC: June 2020 Both 18 to 75 Yrs. China 10- NCT043 46,368 Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID19) I and II Not Recruiting 20 BM-MSCs DOS: April 2020 DOC: December 2020 Both 18 to 75 Yrs. China 11- NCT043 52,803 Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020 DOC: April 2026 Both 18 to 90 Yrs. – 12- NCT043 49,631 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 56 AD-MSCs DOS: May 2020 DOC: December 2020 Both Child, Adult, Older Adult United States 13- NCT030 42,143 Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID19) (REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019 DOC: October 2022 Both 16 Yrs. and older United Kingdom 14- NCT043 90,152 Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020 DOC: May 2021 Both 18 to 80 Yrs. Colombia 15- NCT043 82,547 Treatment of COVID19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosaderived Mesenchymal Stem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020 DOC: June 2021 Both 18 to70 Yrs. Belarus 16- NCT043 66,323 Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020 DOC: October 2021 Both 18 to 80 Yrs. – 17- NCT043 66,063 Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020 DOC: December 2020 Both 18 to 65 Yrs. Iran 18- NCT043 77,334 Mesenchymal Stem Cells (MSCs) in Inflammation- Resolution Programs of Coronavirus Disease 2019 (COVID19) Induced Acute Respiratory Distress Syndrome (ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020 DOC: February 2021 Both 18 Yrs. and older Germany 19- NCT043 71,393 MSCs in COVID19 ARDS III Recruiting 300 MSCs Remestemcel-L DOS: April 30, 2020 DOC: April 2022 Both 18 Yrs. and older United States 20- NCT043 62,189 Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020 DOC: October 2020 Both Child, Adult, Older Adult United States 21- NCT043 66,271 Clinical Trial of Allogeneic Mesenchymal Cells from Umbilical Cord Tissue in Patients with COVID19 II Recruiting 106 UC-MSCs DOS: May 2020 DOC: May 2021 Both 40 to 80 Yrs. Spain 22- NCT043 48,435 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020 DOC: April 2021 Both Child, Adult, Older Adult United States 23- NCT043 71,601 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020 DOC: December 2022 Both 18 to 70 Yrs. China 24- NCT043 55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020 DOC: May 2021 Both 18 Yrs. and older United States 25- NCT043 92,778 Clinical Use of Stem Cells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020 DOC: September 2020 Both 40 to 60 Yrs. Turkey 26- NCT043 97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020 DOC: June 2021 Both 18 to 80 Yrs. – 27- NCT043 90,139 Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients with Respiratory Distress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020 DOC: December 2020 Both 18 to 75 Yrs. Spain 28- NCT042 69,525 Umbilical Cord (UC)- Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020 DOC: September 2020 Both 18 to 75 Yrs. China
label	Table 1
caption	Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020
p	Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020
table	S.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country 1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020 DOC: June 2020 Both 18 Yrs. and older Brazil 2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020 DOC:September 2020 Both 18 Yrs. and older Jordan 3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020 DOC: July 2020 Both 18 to75 Yrs. China 4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020 DOC: July 2021 Both 18 to75 Yrs. – 5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020 DOC: December 2021 Both 18 to70 Yrs. China 6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020 DOC: February 2022 Both 18 to 65 Yrs. China 7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs (MSCs-Exo) DOS: February 2020 DOC: July 2020 Both 18 to75 Yrs. – 8- NCT043 36,254 Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020 DOC: March 2021 Both 18 to 65 Yrs. China 9- NCT043 39,660 Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020 DOC: June 2020 Both 18 to 75 Yrs. China 10- NCT043 46,368 Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID19) I and II Not Recruiting 20 BM-MSCs DOS: April 2020 DOC: December 2020 Both 18 to 75 Yrs. China 11- NCT043 52,803 Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020 DOC: April 2026 Both 18 to 90 Yrs. – 12- NCT043 49,631 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 56 AD-MSCs DOS: May 2020 DOC: December 2020 Both Child, Adult, Older Adult United States 13- NCT030 42,143 Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID19) (REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019 DOC: October 2022 Both 16 Yrs. and older United Kingdom 14- NCT043 90,152 Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020 DOC: May 2021 Both 18 to 80 Yrs. Colombia 15- NCT043 82,547 Treatment of COVID19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosaderived Mesenchymal Stem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020 DOC: June 2021 Both 18 to70 Yrs. Belarus 16- NCT043 66,323 Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020 DOC: October 2021 Both 18 to 80 Yrs. – 17- NCT043 66,063 Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020 DOC: December 2020 Both 18 to 65 Yrs. Iran 18- NCT043 77,334 Mesenchymal Stem Cells (MSCs) in Inflammation- Resolution Programs of Coronavirus Disease 2019 (COVID19) Induced Acute Respiratory Distress Syndrome (ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020 DOC: February 2021 Both 18 Yrs. and older Germany 19- NCT043 71,393 MSCs in COVID19 ARDS III Recruiting 300 MSCs Remestemcel-L DOS: April 30, 2020 DOC: April 2022 Both 18 Yrs. and older United States 20- NCT043 62,189 Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020 DOC: October 2020 Both Child, Adult, Older Adult United States 21- NCT043 66,271 Clinical Trial of Allogeneic Mesenchymal Cells from Umbilical Cord Tissue in Patients with COVID19 II Recruiting 106 UC-MSCs DOS: May 2020 DOC: May 2021 Both 40 to 80 Yrs. Spain 22- NCT043 48,435 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020 DOC: April 2021 Both Child, Adult, Older Adult United States 23- NCT043 71,601 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020 DOC: December 2022 Both 18 to 70 Yrs. China 24- NCT043 55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020 DOC: May 2021 Both 18 Yrs. and older United States 25- NCT043 92,778 Clinical Use of Stem Cells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020 DOC: September 2020 Both 40 to 60 Yrs. Turkey 26- NCT043 97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020 DOC: June 2021 Both 18 to 80 Yrs. – 27- NCT043 90,139 Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients with Respiratory Distress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020 DOC: December 2020 Both 18 to 75 Yrs. Spain 28- NCT042 69,525 Umbilical Cord (UC)- Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020 DOC: September 2020 Both 18 to 75 Yrs. China
tr	S.No. Clinical trial number Study Title Phase Status Sample Size(n) CellularInterventions Date of Start (DOS)Date of Completion (DOC) Gender(Male/Female/ Both) Age Country
th	S.No.
th	Clinical trial number
th	Study Title
th	Phase
th	Status
th	Sample Size(n)
th	CellularInterventions
th	Date of Start (DOS)Date of Completion (DOC)
th	Gender(Male/Female/ Both)
th	Age
th	Country
tr	1- NCT04315987 Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia I Not Recruiting 66 Nest Cell ® DOS: April 2020 DOC: June 2020 Both 18 Yrs. and older Brazil
td	1-
td	NCT04315987
td	Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 Pneumonia
td	I
td	Not Recruiting
td	66
td	Nest Cell ®
td	DOS: April 2020 DOC: June 2020
p	DOS: April 2020
p	DOC: June 2020
td	Both
td	18 Yrs. and older
td	Brazil
tr	2- NCT04313322 Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells I Recruiting 5 WJ-MSCs DOS: March 2020 DOC:September 2020 Both 18 Yrs. and older Jordan
td	2-
td	NCT04313322
td	Treatment of COVID19 Patients Using Wharton’s Jelly- Mesenchymal Stem Cells
td	I
td	Recruiting
td	5
td	WJ-MSCs
td	DOS: March 2020 DOC:September 2020
p	DOS: March 2020
p	DOC:September 2020
td	Both
td	18 Yrs. and older
td	Jordan
tr	3- NCT04288102 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19) II Recruiting 90 MSCs DOS: March 2020 DOC: July 2020 Both 18 to75 Yrs. China
td	3-
td	NCT04288102
td	Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19)
td	II
td	Recruiting
td	90
td	MSCs
td	DOS: March 2020 DOC: July 2020
p	DOS: March 2020
p	DOC: July 2020
td	Both
td	18 to75 Yrs.
td	China
tr	4- NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells Early phaseI Not Recruiting 24 DPSCs DOS: March 2020 DOC: July 2021 Both 18 to75 Yrs. –
td	4-
td	NCT04302519
td	Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells
td	Early phaseI
td	Not Recruiting
td	24
td	DPSCs
td	DOS: March 2020 DOC: July 2021
p	DOS: March 2020
p	DOC: July 2021
td	Both
td	18 to75 Yrs.
td	–
tr	5- NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus I Recruiting 20 MSCs DOS: January 2020 DOC: December 2021 Both 18 to70 Yrs. China
td	5-
td	NCT04252118
td	Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus
td	I
td	Recruiting
td	20
td	MSCs
td	DOS: January 2020 DOC: December 2021
p	DOS: January 2020
p	DOC: December 2021
td	Both
td	18 to70 Yrs.
td	China
tr	6- NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia – Not Recruiting 48 UC-MSCs DOS: April 2020 DOC: February 2022 Both 18 to 65 Yrs. China
td	6-
td	NCT04273646
td	Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia
td	–
td	Not Recruiting
td	48
td	UC-MSCs
td	DOS: April 2020 DOC: February 2022
p	DOS: April 2020
p	DOC: February 2022
td	Both
td	18 to 65 Yrs.
td	China
tr	7- NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia I Not Recruiting 30 Exosomes derived from AD-MSCs (MSCs-Exo) DOS: February 2020 DOC: July 2020 Both 18 to75 Yrs. –
td	7-
td	NCT04276987
td	A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia
td	I
td	Not Recruiting
td	30
td	Exosomes derived from AD-MSCs (MSCs-Exo)
p	Exosomes derived from AD-MSCs
p	(MSCs-Exo)
td	DOS: February 2020 DOC: July 2020
p	DOS: February 2020
p	DOC: July 2020
td	Both
td	18 to75 Yrs.
td	–
tr	8- NCT043 36,254 Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID19 Patients I and II Recruiting 20 DPSCs DOS: April 2020 DOC: March 2021 Both 18 to 65 Yrs. China
td	8-
td	NCT043 36,254
p	NCT043
p	36,254
td	Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID19 Patients
p	Safety and Efficacy
p	Study of Allogeneic
p	Human Dental Pulp
p	Mesenchymal Stem
p	Cells to Treat Severe
p	COVID19 Patients
td	I and II
td	Recruiting
td	20
td	DPSCs
td	DOS: April 2020 DOC: March 2021
p	DOS: April 2020
p	DOC: March
p	2021
td	Both
td	18 to 65 Yrs.
td	China
tr	9- NCT043 39,660 Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID19 Pneumonia I and II Recruiting 30 UC-MSCs DOS: February 2020 DOC: June 2020 Both 18 to 75 Yrs. China
td	9-
td	NCT043 39,660
p	NCT043
p	39,660
td	Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID19 Pneumonia
p	Clinical Research of Human Mesenchymal
p	Stem Cells in the Treatment of COVID19 Pneumonia
td	I and II
td	Recruiting
td	30
td	UC-MSCs
td	DOS: February 2020 DOC: June 2020
p	DOS: February 2020
p	DOC: June 2020
td	Both
td	18 to 75 Yrs.
td	China
tr	10- NCT043 46,368 Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID19) I and II Not Recruiting 20 BM-MSCs DOS: April 2020 DOC: December 2020 Both 18 to 75 Yrs. China
td	10-
td	NCT043 46,368
p	NCT043
p	46,368
td	Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID19)
p	Bone Marrow-Derived
p	Mesenchymal Stem
p	Cell Treatment for
p	Severe Patients With
p	Coronavirus Disease
p	2019 (COVID19)
td	I and II
td	Not Recruiting
p	Not
p	Recruiting
td	20
td	BM-MSCs
td	DOS: April 2020 DOC: December 2020
p	DOS: April 2020
p	DOC: December
p	2020
td	Both
td	18 to 75 Yrs.
td	China
tr	11- NCT043 52,803 Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease I Not Recruiting 20 AD-MSCs DOS: April 2020 DOC: April 2026 Both 18 to 90 Yrs. –
td	11-
td	NCT043 52,803
p	NCT043
p	52,803
td	Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease
p	Adipose Mesenchymal
p	Cells for Abatement of
p	SARS CoV-2
p	Respiratory
p	Compromise in
p	COVID-19 Disease
td	I
td	Not Recruiting
td	20
td	AD-MSCs
td	DOS: April 2020 DOC: April 2026
p	DOS: April 2020
p	DOC: April 2026
td	Both
td	18 to 90 Yrs.
td	–
tr	12- NCT043 49,631 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 56 AD-MSCs DOS: May 2020 DOC: December 2020 Both Child, Adult, Older Adult United States
td	12-
td	NCT043 49,631
p	NCT043
p	49,631
td	A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19
p	A Clinical Trial to
p	Determine the Safety
p	and Efficacy of Hope
p	Biosciences
p	Autologous
p	Mesenchymal Stem
p	Cell Therapy (HBadMSCs)
p	to Provide
p	Protection Against
p	COVID19
td	II
td	Enrolling by invitation
p	Enrolling by
p	invitation
td	56
td	AD-MSCs
td	DOS: May 2020 DOC: December 2020
p	DOS: May 2020
p	DOC: December 2020
td	Both
td	Child, Adult, Older Adult
p	Child, Adult,
p	Older
p	Adult
td	United States
tr	13- NCT030 42,143 Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID19) (REALIST) I and II Recruiting 75 UC derived CD362 enriched MSCs DOS: January 2019 DOC: October 2022 Both 16 Yrs. and older United Kingdom
td	13-
td	NCT030 42,143
p	NCT030
p	42,143
td	Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID19) (REALIST)
p	Repair of Acute
p	Respiratory Distress
p	Syndrome by Stromal
p	Cell Administration
p	(REALIST) (COVID19)
p	(REALIST)
td	I and II
td	Recruiting
td	75
td	UC derived CD362 enriched MSCs
td	DOS: January 2019 DOC: October 2022
p	DOS: January 2019
p	DOC: October 2022
td	Both
td	16 Yrs. and older
td	United Kingdom
tr	14- NCT043 90,152 Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome due to COVID19 I and II Not Recruiting 40 WJ-MSCs DOS: June 2020 DOC: May 2021 Both 18 to 80 Yrs. Colombia
td	14-
td	NCT043 90,152
p	NCT043
p	90,152
td	Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome due to COVID19
p	Safety and Efficacy of Intravenous Wharton’s
p	Jelly Derived
p	Mesenchymal Stem
p	Cells in Acute
p	Respiratory Distress
p	Syndrome due to COVID19
td	I and II
td	Not Recruiting
td	40
td	WJ-MSCs
td	DOS: June 2020 DOC: May 2021
p	DOS: June 2020
p	DOC: May 2021
td	Both
td	18 to 80 Yrs.
td	Colombia
tr	15- NCT043 82,547 Treatment of COVID19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosaderived Mesenchymal Stem Cells I and II Not Recruiting 40 OM-MSCs DOS: May 2020 DOC: June 2021 Both 18 to70 Yrs. Belarus
td	15-
td	NCT043 82,547
p	NCT043
p	82,547
td	Treatment of COVID19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosaderived Mesenchymal Stem Cells
p	Treatment of
p	COVID19 Associated
p	Pneumonia with
p	Allogenic Pooled
p	Olfactory Mucosaderived
p	Mesenchymal
p	Stem Cells
td	I and II
td	Not Recruiting
td	40
td	OM-MSCs
td	DOS: May 2020 DOC: June 2021
p	DOS: May 2020
p	DOC: June 2021
td	Both
td	18 to70 Yrs.
td	Belarus
tr	16- NCT043 66,323 Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients with Severe Pneumonia due to COVID19 I and II Not Recruiting 26 AD-MSCs DOS: April 2020 DOC: October 2021 Both 18 to 80 Yrs. –
td	16-
td	NCT043 66,323
p	NCT043
p	66,323
td	Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients with Severe Pneumonia due to COVID19
p	Clinical Trial to Assess
p	the Safety and
p	Efficacy of Intravenous
p	Administration of Allogeneic Adult
p	Mesenchymal Stem
p	Cells of Expanded
p	Adipose Tissue in Patients with Severe Pneumonia due to COVID19
td	I and II
td	Not Recruiting
td	26
td	AD-MSCs
td	DOS: April 2020 DOC: October 2021
p	DOS: April 2020
p	DOC: October 2021
td	Both
td	18 to 80 Yrs.
td	–
tr	17- NCT043 66,063 Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome II and III Recruiting 60 MSCs, and Exosomes derived from MSCs (MSCs-Exo) DOS: April 2020 DOC: December 2020 Both 18 to 65 Yrs. Iran
td	17-
td	NCT043 66,063
p	NCT043
p	66,063
td	Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome
p	Mesenchymal Stem
p	Cell Therapy for SARS-CoV-2-related
p	Acute Respiratory
p	Distress Syndrome
td	II and III
td	Recruiting
td	60
td	MSCs, and Exosomes derived from MSCs (MSCs-Exo)
td	DOS: April 2020 DOC: December 2020
p	DOS: April 2020
p	DOC: December 2020
td	Both
td	18 to 65 Yrs.
td	Iran
tr	18- NCT043 77,334 Mesenchymal Stem Cells (MSCs) in Inflammation- Resolution Programs of Coronavirus Disease 2019 (COVID19) Induced Acute Respiratory Distress Syndrome (ARDS) II Not Recruiting 40 BM-MSCs DOS: May 2020 DOC: February 2021 Both 18 Yrs. and older Germany
td	18-
td	NCT043 77,334
p	NCT043
p	77,334
td	Mesenchymal Stem Cells (MSCs) in Inflammation- Resolution Programs of Coronavirus Disease 2019 (COVID19) Induced Acute Respiratory Distress Syndrome (ARDS)
p	Mesenchymal Stem
p	Cells (MSCs) in Inflammation-
p	Resolution Programs
p	of Coronavirus
p	Disease 2019
p	(COVID19) Induced
p	Acute Respiratory
p	Distress Syndrome
p	(ARDS)
td	II
td	Not Recruiting
td	40
td	BM-MSCs
td	DOS: May 2020 DOC: February 2021
p	DOS: May 2020
p	DOC: February 2021
td	Both
td	18 Yrs. and older
td	Germany
tr	19- NCT043 71,393 MSCs in COVID19 ARDS III Recruiting 300 MSCs Remestemcel-L DOS: April 30, 2020 DOC: April 2022 Both 18 Yrs. and older United States
td	19-
td	NCT043 71,393
p	NCT043
p	71,393
td	MSCs in COVID19 ARDS
p	MSCs in COVID19
p	ARDS
td	III
td	Recruiting
td	300
td	MSCs Remestemcel-L
p	MSCs
p	Remestemcel-L
td	DOS: April 30, 2020 DOC: April 2022
p	DOS: April 30, 2020
p	DOC: April 2022
td	Both
td	18 Yrs. and older
td	United States
tr	20- NCT043 62,189 Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID19 II Not Recruiting 110 AD-MSCs DOS: May 2020 DOC: October 2020 Both Child, Adult, Older Adult United States
td	20-
td	NCT043 62,189
p	NCT043
p	62,189
td	Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID19
p	Efficacy and Safety
p	Study of Allogeneic
p	HB-adMSCs for the Treatment of COVID19
td	II
td	Not Recruiting
td	110
td	AD-MSCs
td	DOS: May 2020 DOC: October 2020
p	DOS: May 2020
p	DOC: October 2020
td	Both
td	Child, Adult, Older Adult
p	Child,
p	Adult,
p	Older
p	Adult
td	United States
tr	21- NCT043 66,271 Clinical Trial of Allogeneic Mesenchymal Cells from Umbilical Cord Tissue in Patients with COVID19 II Recruiting 106 UC-MSCs DOS: May 2020 DOC: May 2021 Both 40 to 80 Yrs. Spain
td	21-
td	NCT043 66,271
p	NCT043
p	66,271
td	Clinical Trial of Allogeneic Mesenchymal Cells from Umbilical Cord Tissue in Patients with COVID19
p	Clinical Trial of
p	Allogeneic
p	Mesenchymal Cells
p	from Umbilical Cord
p	Tissue in Patients with
p	COVID19
td	II
td	Recruiting
td	106
td	UC-MSCs
td	DOS: May 2020 DOC: May 2021
p	DOS: May 2020
p	DOC: May 2021
td	Both
td	40 to 80 Yrs.
td	Spain
tr	22- NCT043 48,435 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020 DOC: April 2021 Both Child, Adult, Older Adult United States
td	22-
td	NCT043 48,435
p	NCT043
p	48,435
td	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HBadMSCs) to Provide Protection Against COVID19
p	A Randomized,
p	Double-Blind,
p	Placebo-Controlled
p	Clinical Trial to Determine the Safety and Efficacy of Hope
p	Biosciences
p	Allogeneic
p	Mesenchymal Stem
p	Cell Therapy (HBadMSCs) to Provide Protection Against COVID19
td	II
td	Enrolling by invitation
td	100
td	AD-MSCs
td	DOS: April 2020 DOC: April 2021
p	DOS: April 2020
p	DOC: April 2021
td	Both
td	Child, Adult, Older Adult
p	Child,
p	Adult, Older
p	Adult
td	United States
tr	23- NCT043 71,601 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 Early Phase I Active not Recruiting 60 UC-MSCs DOS: March 2020 DOC: December 2022 Both 18 to 70 Yrs. China
td	23-
td	NCT043 71,601
p	NCT043
p	71,601
td	Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019
p	Safety and Effectiveness of Mesenchymal Stem
p	Cells in the Treatment of Pneumonia of Coronavirus Disease 2019
td	Early Phase I
td	Active not Recruiting
td	60
td	UC-MSCs
td	DOS: March 2020 DOC: December 2022
p	DOS: March 2020
p	DOC: December 2022
td	Both
td	18 to 70 Yrs.
td	China
tr	24- NCT043 55,728 Use of UC-MSCs for COVID19 Patients I and II Recruiting 24 UC-MSCs DOS: April 2020 DOC: May 2021 Both 18 Yrs. and older United States
td	24-
td	NCT043 55,728
p	NCT043
p	55,728
td	Use of UC-MSCs for COVID19 Patients
td	I and II
td	Recruiting
td	24
td	UC-MSCs
td	DOS: April 2020 DOC: May 2021
p	DOS: April 2020
p	DOC: May 2021
td	Both
td	18 Yrs. and older
td	United States
tr	25- NCT043 92,778 Clinical Use of Stem Cells for the Treatment of COVID19 I and II Recruiting 30 UC-MSCs DOS: April 2020 DOC: September 2020 Both 40 to 60 Yrs. Turkey
td	25-
td	NCT043 92,778
p	NCT043
p	92,778
td	Clinical Use of Stem Cells for the Treatment of COVID19
p	Clinical Use of Stem
p	Cells for the Treatment of COVID19
td	I and II
td	Recruiting
td	30
td	UC-MSCs
td	DOS: April 2020 DOC: September 2020
p	DOS: April 2020
p	DOC: September 2020
td	Both
td	40 to 60 Yrs.
td	Turkey
tr	26- NCT043 97,796 Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation I Not Recruiting 45 BM-MSCs DOS: June 2020 DOC: June 2021 Both 18 to 80 Yrs. –
td	26-
td	NCT043 97,796
p	NCT043
p	97,796
td	Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical Ventilation
td	I
td	Not Recruiting
td	45
td	BM-MSCs
td	DOS: June 2020 DOC: June 2021
p	DOS: June 2020
p	DOC: June 2021
td	Both
td	18 to 80 Yrs.
td	–
tr	27- NCT043 90,139 Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients with Respiratory Distress to COVID19 I and II Recruiting 30 WJ-MSCs DOS: May 2020 DOC: December 2020 Both 18 to 75 Yrs. Spain
td	27-
td	NCT043 90,139
p	NCT043
p	90,139
td	Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients with Respiratory Distress to COVID19
p	Efficacy and Safety
p	Evaluation of Mesenchymal Stem
p	Cells for the Treatment of Patients
p	with Respiratory
p	Distress to COVID19
td	I and II
td	Recruiting
td	30
td	WJ-MSCs
td	DOS: May 2020 DOC: December 2020
p	DOS: May 2020
p	DOC: December 2020
td	Both
td	18 to 75 Yrs.
td	Spain
tr	28- NCT042 69,525 Umbilical Cord (UC)- Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia II Recruiting 10 UC-MSCs DOS: February 2020 DOC: September 2020 Both 18 to 75 Yrs. China
td	28-
td	NCT042 69,525
p	NCT042
p	69,525
td	Umbilical Cord (UC)- Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia
p	Umbilical Cord (UC)- Derived Mesenchymal
p	Stem Cells (MSCs)
p	Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia
td	II
td	Recruiting
td	10
td	UC-MSCs
td	DOS: February 2020 DOC: September 2020
p	DOS: February 2020
p	DOC: September 2020
td	Both
td	18 to 75 Yrs.
td	China
p	Interestingly, the data obtained from a single-center, open-labeled pilot investigation in COVID19 patients from China demonstrated that the treatment with MSCs improved disease-associated parameters in severe and critically severe patients [16]. To brief, seven patients (one critically severe, four severe, and two having common symptoms of pneumonia) were enrolled in the treatment group, where as three patients served as placebo controls (all displaying severe symptoms). All treated patients received a single dose of 1X106 MSCs/kg body weight. Remarkably, all seven showed improvement over two weeks with no noticeable adverse effect, thereby, demonstrated the safe and effective infusion of ACE2–ve MSCs in COVID19 pneumonia patients. The overall improvement in the MSCs infused group was striking as within 2 days after treatment pulmonary functions and symptoms of all the seven patients significantly improved, and most tested negative for the SARS-CoV-2 nucleic acid test over two weeks after MSCs infusion. After 6 days of infusion, the therapy inhibited the over-activation of the immune system by inhibiting CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells. It also decreased TNF-α and enhanced the number of peripheral lymphocytes, CD14+CD11c+CD11bmid regulatory DC, and anti-inflammatory cytokine IL-10. Moreover, the gene expression profile revealed that MSC was ACE2-ve and TMPRSS2-ve, which indicates that the MSCs would not be susceptible to SARS-CoV2 infection. Finally, the RNA sequencing and gene expression analysis showed that MSCs were closely involved in the anti-viral pathways, and had anti-inflammatory trophic activities [6]. In line with above findings, the results from a case report on COVID19 [16] and a study on influenza virus H9NA [5], which shares complications similar to COVID19 like ARDS and lung failure, demonstrated that MSCs can offer therapy for virally-induced pulmonary complications in clinical settings. While all these studies have provided new insights into the protective mechanism of MSCs during viral infection, a few short comings were noticed in these treatments. For example, similar to study conducted by ADSCC, there is also a lack of information on MSCs processing and screening before infusion, and the long-term follow-up of patients etc. For a protocol to be implicated in a larger cohort, optimal information regarding MSCs as well as patients needs to be investigated in a rationally designed controlled setting. Concerning the underlying mechanism by which MSCs exert a beneficial effect, the ability to home [17], engraft [17] and transdifferentiate into the target tissue, which is the infected lung in the present case, besides the bystander effect and immunomodulatory potential [9, 18, 19], are well documented. Also, the anti-apoptotic, anti-viral, and anti-bacterial functions of this therapy have been well known [20]. Under homeostatic conditions, MSCs are hypo-immunogenic and have immune evasion capabilities [21], indicating their suitability for allogeneic transplantation.
p	Despite years of success in MSC research, some of the challenges faced for successful transplantation therapy include heterogeneous treatment response, low number, and source-specific immunomodulatory response [22]. Interestingly, the reparative effects noticed in vivo indicate that clinical efficacy depends on the microenvironment of the transplants [23]. Therefore, the therapeutic capability of MSCs can be regulated and is an attractive area for investigation. However, resting stage MSCs do not show the above potentials; it is only when they are exposed to a stimuli milieu, they demonstrate immunomodulatory or homing potentials [24, 25]. This indicates that the modulatory activity is not constitutively expressed by MSCs but is determined by the process of ‘priming’ to be obtained. Therefore, the empowerment of MSCs by priming before a clinical application may be a potential solution to overcome the challenges that hinder the effectiveness of MSC outcomes. Priming, with inflammatory cytokines, is a process to modulate biological, biochemical or biophysical features that can influence cell fate [26, 27]. In recent years, several approaches have been proposed to improve the effectiveness, endurance and therapeutic efficiency of MSCs [28, 29]. Worth mentioning, the approaches utilizing MSCs, and especially the primed MSCs, could be vital for the success of cell therapy in lung complications, as the intravenously infused MSCs often get trapped in the lung; however, the retention time of MSCs within the lung is extremely short [30]. Though, the alteration in holding capacity of lung in a diseased scenario cannot be ruled out. As primed MSCs could efficiently enhance retention [31], beside intensifying homing [17], and survival [32] in damaged lung, therefore, activation via priming could be a crucial mechanism for retention and engraftment of MSCs in a diseased lung, subsequently providing benefits to the lung through multiple mechanisms.
p	Priming perspectives and MSCs robustness are currently under development. Pre-treating MSCs before injection may enhance the expression of fitness markers and stimulate greater therapeutic outcome. For instance, reports suggest cytokine mediated activation of MSCs lead to strong immunosuppressive behavior, and thereby attenuation of lung injury in rodents [31, 33], however some contradictory findings are also available as no effective role of proinflammatory cytokine priming was observed on MSCs in a model of acute lung injury and ARDS [34]. Therefore, the effect of cytokine priming needs to be further verified to prove the efficacy of primed MSCs in lung anomalies. Besides cytokines, priming of MSCs by growth factors is also a potent mechanism for MSC activation before infusion in pulmonary diseases [35]. Likewise, hypoxia preconditioning can also improve the proliferation and therapeutic efficacy of MSCs, as evident in bleomycin-induced pulmonary fibrosis model [36]. Further, employing pharmacological agents such as paclitaxel to prime MSCs could also be helpful in improving lung anomalies [37]. Therefore, in line with above findings it could reasonably by presume that MSC priming is a significant approach for treating pulmonary anomalies. In the light of above findings, herein, we propose that the mechanism of priming of MSC could be implied to the following: i) Licensing by pro-inflammatory cytokines such as IFN-γ, TNF-α, etc., to enhance immunosuppressive potential; ii) Priming by non-cytokines stimuli such as hormones/growth factors like HGF to boost defensive and protective cellular mechanisms; iii) Pre-conditioning by hypoxia, and/or pharmacological agents, e.g., sphingosine-1-phosphate, etc., to enhance engraftment and reparative effects; iv) Activation by spheroid culturing to enhance homing, survival, differentiation, and lineage specificity e.g. angiogenic mechanism; v) The timing of MSCs engraftment and engagement in the process of activation of immune cells to achieve the most excellent beneficial effect of MSCs infusion.
p	Nevertheless, there are several limitations associated with the priming approaches that may jeopardize MSC based therapies at clinics; hence these challenges must be overcome to harness the true potential of MSCs. For instance, the priming of MSCs by proinflammatory cytokines may negatively affect the MHC class I and class II level; Hormones and/or growth factors may affect the differentiation capacity of MSCs; Priming by hypoxia may induce oxidative stress in MSCs; Growth factors may negatively affect the differentiation capacity of MSCs; Spheroid cultures owing to the variability in their size may lead to the necrotic spheroid core, thus, may interfere with the effectiveness of MSCs after transplantation. Further, the variations in results due to the heterogeneous nature of MSCs [23], and high cost associated with priming protocols, etc., are the considerable hindrances in the successful translation of primed MSCs to the clinic. For instance, not all the priming stimulus, even the same stimuli, shows a similar effect on the cells. Therefore, the effect of individual licensing stimuli should be accessed before being employed at a manufacturing scale. For example, IFN-γ can inhibit T cell proliferation in the regulation of MSC-mediated immunosuppression [38] and can also increase the capacity of MSCs to produce different subtypes of Tregs [39]. IFN-γ can also promote increased expressions of VCAM-1 and ICAM-1 on the surface of MSCs [40]. Similarly, the adjustment of MSC infusion timing may reveal the accurate description of inflammatory surroundings related to a specific disease [41]. This may also explain why MSCs do not always exhibit beneficial effects, even in the same disease. Therefore, it is of great importance to choose the right stimuli in the right dose at and for the right timing, besides fitness of MSCs, fresh vs. cryopreserved, MSCs passage number, and route of delivery to assure homogenous clinical outcomes (Fig. 1). Fig. 1 Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)
figure	Fig. 1 Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)
label	Fig. 1
caption	Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)
p	Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)
p	To conclude, since its emergence, COVID19 has turned out to be the top priority of the healthcare system. Although stem cell treatment has not yet been proven to eliminate coronavirus completely, preliminary results are promising, suggesting that the diseased patients, under the treatment, might be more amenable to survive the infection. The effect of priming on MSCs’ therapeutic potential has been extensively researched and continues to be investigated. The results of such efforts are eagerly anticipated, as these will pave a way for a strong foundation for future scientific research and clinical applications for a variety of diseases including pulmonary complications. Finally, bearing in mind the desires for mitigation of the existing pandemic, the effectiveness of MSCs in virally infected acute respiratory diseases symptoms, and the pieces of evidence from priming strategies for MSCs, we hypothesize that endorsing priming may enhance the effectiveness of MSCs for long-term benefits which is a prerequisite for the success of stem cell therapy in COVID19 patients.
back	Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. We extend our thanks to Mr. Hari Shankar, Era University, for the precious suggestions and support in writing this manuscript. Author Contributions SSR designed, drafted and edited the manuscript. PS and MAK reviewed the manuscript. All the authors have approved the final article. Funding Information This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Compliance with Ethical Standards Disclosure of Competing Interest The authors declare no conflicts of interest. Abbreviations IL-2 interleukin 2 IL-6 interleukin 6 IL-7 interleukin 7 IL-10 interleukin 10 IFN-γ Interferon gamma TNF-α Tumor Necrosis Factor alpha MCP-1 Monocyte Chemoattractant Protein 1 MIP-1α Macrophage Inflammatory Proteins 1 alpha GCSF Granulocyte Colony Stimulating Factor VCAM-1 Vascular Cell Adhesion Molecule-1 ICAM-1 Intracelullar Adhesion Molecule-1 HGF Hepatocyte growth factor BM-MSC Bone Marrow derived Mesenchymal Stem Cell AD-MSC Adipose derived Mesenchyma l Stem Cell UC-MSC Umbilical Cord derived Mesenchymal Stem Cell WJ-MSC Warton Jelly derived Mesenchymal Stem Cell OM-MSC Olfactory Mucosa derived Mesenchymal Stem Cell DPSC Dental Pulp Stem Cell NK Cells Natural Killer Cells DC Dendritic Cells
footnote	Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
p	Publisher’s Note
p	Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
ack	We extend our thanks to Mr. Hari Shankar, Era University, for the precious suggestions and support in writing this manuscript.
p	We extend our thanks to Mr. Hari Shankar, Era University, for the precious suggestions and support in writing this manuscript.
notes	Author Contributions SSR designed, drafted and edited the manuscript. PS and MAK reviewed the manuscript. All the authors have approved the final article.
title	Author Contributions
p	SSR designed, drafted and edited the manuscript. PS and MAK reviewed the manuscript. All the authors have approved the final article.
notes	Funding Information This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
title	Funding Information
p	This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
notes	Compliance with Ethical Standards Disclosure of Competing Interest The authors declare no conflicts of interest.
title	Compliance with Ethical Standards
notes	Disclosure of Competing Interest The authors declare no conflicts of interest.
title	Disclosure of Competing Interest
p	The authors declare no conflicts of interest.
title	Abbreviations
p	interleukin 2
p	interleukin 6
p	interleukin 7
p	interleukin 10
p	Interferon gamma
p	Tumor Necrosis Factor alpha
p	Monocyte Chemoattractant Protein 1
p	Macrophage Inflammatory Proteins 1 alpha
p	Granulocyte Colony Stimulating Factor
p	Vascular Cell Adhesion Molecule-1
p	Intracelullar Adhesion Molecule-1
p	Hepatocyte growth factor
p	Bone Marrow derived Mesenchymal Stem Cell
p	Adipose derived Mesenchyma l Stem Cell
p	Umbilical Cord derived Mesenchymal Stem Cell
p	Warton Jelly derived Mesenchymal Stem Cell
p	Olfactory Mucosa derived Mesenchymal Stem Cell
p	Dental Pulp Stem Cell
p	Natural Killer Cells
p	Dendritic Cells

Annnotations TAB TSV DIC JSON TextAE

last updated at 2021-06-18 20:44:34 UTC

Denotations: 0
Blocks: 0
Relations: 0

PMC:7317273 / 12448-12455 JSONTXT 2 Projects

Document structure show

Annnotations TAB TSV DIC JSON TextAE

PMC:7317273 / 12448-12455 JSON TXT 2 Projects